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Abstract 
Hanna Ollila, Genetics of sleep, Sleep and Comorbidities: Connection at the Genetic 
Level. National Institute for Health and Welfare. Research 96. 166 pages. Helsinki, 
Finland 1.2. 2013. 
ISBN 978-952-245-812-4 (printed); ISBN 978-952-245-813-1 (pdf) 
 
Sleep is a complex genetic trait with substantial heritability of up to 44%. Sleep 
problems are increasing in the society and the average sleep duration has been 
decreasing gradually during the past decades. At the same time the amount of 
cardiometabolic and psychiatric diseases has steadily increased. The common 
genetic variants contributing to sleep duration are largely unknown and we still do 
not know why we sleep. Recent advantages in genetics have provided the scientific 
community with the tools to elucidate the genes behind complex genetic traits as 
well. In this thesis, the traditional candidate gene approach as well as genome-wide 
tools combined with functional analysis were used to study the normal variation in 
sleep duration (I), consequences of sleep loss (I) and finally the connection of sleep 
with co-morbid diseases in humans (II-IV).  
Genetic variation behind normal sleep duration was studied using genome-wide 
association (GWAS) (I). The function of the variants was elucidated using RNA 
expression in population level. In addition, the variants that showed nominally 
significant association in the follow up sample were studied using RNA expression 
after experimentally induced sleep restriction (I). The original GWAS did not 
produce genome-wide significant findings. However, recent studies have shown that 
part of the association signals reaching only suggestive levels of association may be 
of biological relevance. We thus followed up the top 32 signals with suggestive 
evidence for association in a follow-up sample of 6834 individuals. Out of these, 
three SNPs with point wise P<0.05 associated with normal sleep duration. The SNPs 
were located near genes encoding for Krüppel like factor 6 (KLF6), protein tyrosine 
phosphatise receptor type U (PTPRU) and between centidin 1 (CENTD1) and 
protocadherin 7 (PCDH7). KLF6 variant associated with shorter sleep duration and 
KLF6 expression levels associated with shorter sleep duration. Accordingly, 
experimental sleep restriction increased KLF6 expression levels. Furthermore, the 
expression levels of KLF6 associated with increased slow wave sleep duration. This 
suggests that the variant in KLF6 may contribute to normal sleep duration via 
increased KLF6 expression and increased sleep intensity (I). However, the findings 
obtained from the GWAS should be interpreted with caution due to the relatively 
small number of individuals in the discovery data set and lack of genome-wide 
significant findings. 
The changes in the RNA expression after experimental sleep restriction revealed 
cellular activation of immune reaction and down regulation of cholesterol and lipid 
metabolism (I and unpublished). Sleep restriction may convey its proatherogenic 
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effects via low grade inflammation and imbalance of metabolism, which previously 
have been related to cardiometabolic diseases. These changes may help to cope with 
short term sleep debt but are likely to induce pathological changes in the long term. 
In order to study the genetic connection of sleep duration with somatic diseases, 
the previously identified genome-wide significant variants associating with blood 
lipid levels were selected for association analysis with sleep duration. Two variants 
near Tribbles1 (TRIB1) associated with sleep duration independently from blood 
lipid levels (II). In addition, TRIB1 RNA expression levels were increased after 
experimental sleep restriction (II). The findings suggest that there are common 
genetic variants, such as those in TRIB1 that may regulate both sleep duration and 
blood lipid levels. The observations of shared genetic regulation both in RNA 
expression and in genetic level may partially explain why sleep duration is related to 
cardiovascular diseases. 
Finally, we evaluated the connection between psychiatric diseases and sleep. A 
common challenge when studying psychiatric phenotypes is the broad spectrum of 
disorders. In addition to the psychiatric diagnosis we studied endophenotypes such 
as insomnia, diurnal preference, seasonality and performance in cognitive tests and 
classified the study subjects in order to get a phenotypically, and also potentially a 
genetically more homogenous study population. One of the key molecules in 
homeostatic sleep regulation is adenosine. Its levels have recently also been related 
with depression. We found adenosine-related genetic polymorphisms that associated 
with depression (III). The findings suggest that the connection of sleep with 
psychiatric diseases may be partially explained by common genetic factors that 
mediate both sleep and psychiatric diseases. This hypothesis was further tested with 
patients suffering from bipolar disorder (BD). In BD, circadian stress such as jet lag 
or shift work can induce manic episodes. We thus tested if the same genetic variants 
associate with BD and with circadian and seasonal phenotypes as well as with 
cognitive task performance. We found variants in Cadherin 7 (CDH7) to associate 
with both sleep phenotypes and with BD. Interestingly, the variants predisposing to 
BD associated with better performance in visual processing, suggesting an 
evolutionary advantage for having the risk allele for BD. Together the findings 
suggest a shared genetic background for regulation of sleep with somatic and 
psychiatric disorders. It is important to identify the genetic factors contributing to 
sleep, together with somatic and psychiatric diseases. The knowledge of biological 
functions creates a strong basis for developing efficient treatments for sleep and 
psychiatric disorders. 
 
 
Keywords: Sleep, polymorphism, RNA expression, cardiovascular disease, mood 
disorders 
 THL — Research 96/2013 11 Genetics of Sleep 
 
Tiivistelmä 
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Uni on monitekijäinen geneettinen ominaisuus, jolla on merkittävä perinnöllinen 
osuus, 44%. Viime aikoina uniongelmat ovat yleistyneet yhteiskunnassa ja 
keskimääräinen unen pituus on vähentynyt. Samaan aikaan Suomessakin yleiset 
sydän- ja verisuonitaudit, tyypin 2 diabetes sekä mielialahäiriöt ovat lisääntyneet. 
Yleiset perinnölliset tekijät sekä yksittäiset geenit, jotka vaikuttavat uneen, ovat 
suurelta osin vielä tuntemattomia. Viimeisen kymmenen vuoden aikana kehitetyt 
uudet geneettiset tutkimusmenetelmät ovat kuitenkin luoneet työkaluja, joilla myös 
monitekijäisten ominaisuuksien tutkiminen on mahdollista. 
Tässä väitöskirjatyössä tutkittiin normaaliin unen pituuteen vaikuttavia yleisiä 
perinnöllisiä tekijöitä suomalaisessa väestössä käyttämällä koko perimän kattavia 
yhden nukleotidin geenimerkkejä (I). Löydökset varmennettiin toistoaineistossa ja 
niiden toimintaa tutkittiin kokeellisissa malleissa populaatiotasolla sekä 
vapaaehtoisilla laboratorio-olosuhteissa (I). Lyhyen unen terveysvaikutuksia 
tutkittiin solutasolta lähtien käyttäen koko genomin RNA-ilmennyskirjastoa 
kokeellisessa ja kontrolloidussa laboratorioympäristössä. Havaittujen yksittäisten 
geenien merkitys väestötasolla mitattiin RNA-ilmentymisellä, jotka yhdistettiin 
mittauksiin unen pituudesta (I ja julkaisemattomat havainnot). Lopulta tutkimme 
unen laadun sekä vuorokausirytmin yhteyttä somaattisiin sairauksiin sekä 
mielialahäiriöihin perinnöllisellä tasolla: liittyvätkö mielialahäiriöissä ja 
somaattisissa sairauksissa toimivat geenit geneettisellä tasolla unen pituuteen tai 
laatuun.  
Havaitsimme, että KLF6, PTPRU sekä CENTD1-PCDH7 geenien läheisyydessä 
olevat geenimuodot liittyvät normaaliin unen pituuteen. Toiminnallinen analyysi 
paljasti lisäksi, että KLF6-geenimuoto liittyy myös KLF6:n ilmentymiseen ja 
lyhytunisilla oli korkeampi KLF6 ilmentyminen populaatiotasolla. Kokeellisessa 
univajeessa löytö toistui ja univaje lisäsi KLF6:n ilmentymistä ja lisäksi liittyi 
suurempaan hidasaaltounen määrään. Tuloksemme viittaavat, että KLF6-geenimuoto 
vaikuttaa unen pituuteen KLF6:n ilmentymisen sekä hidasaaltounen kautta (I).  
RNA-ilmentymistyössä havaitsimme solutasolla puolustusreaktioiden 
käynnistymisen univajeen seurauksena sekä aineenvaihduntatasapainon 
muuttumisen matalammaksi (I ja julkaisemattomat havainnot). Pitkittynyt matalan 
tason puolustusvaste on tunnettu sydän- ja verisuonitautien riskitekijä. Tuloksemme 
osoittavat, että univaje saattaa altistaa sydän- ja verisuonitaudeille 
immuunipuolustuksen käynnistymisellä sekä aiheuttamalla aineenvaihdunnan 
häiriöitä. 
Lisäksi etsimme geenimuotoja, jotka vaikuttavat sekä normaaliin uneen että 
altistavat somaattisille sairauksille. Havaitsimme, että kaksi TRIB1:n lähellä olevaa 
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geenimerkkiä liittyvät veren rasva-aineenvaihdunnan lisäksi normaaliin unen 
säätelyyn (II). Kokeellinen univaje lisäsi myös geenin luentaa (II). 
Lopuksi etsimme geenimuotoja, jotka liittyvät mielialahäiriöihin. Mielialahäiriöissä 
potilaiden ilmiasu on usein laaja. Jotta saisimme ilmiasun selkeämmäksi, tutkimme 
myös tautiin liittyviä ilmiasuja, kuten unettomuutta, väsymystä, vuorokausirytmiä, 
kognitiivisia testejä sekä vuodenaikaisrytmiä. Löysimme masennukseen liittyviä 
geenimuotoja perinteisistä uneen liittyvistä adenosiiniaineenvaihduntaa säätelevistä 
geeneistä (III). Lisäksi löysimme geenejä kaksisuuntaisessa mielialahäiriössä, jotka 
liittyvät kaksisuuntaisen mielialahäiriön lisäksi vuorokausi- ja vuosirytmin 
joustavuuteen sekä kognitiivisiin testeihin (IV). Havaitsimme, että samat 
geenimuodot yllättäen paransivat suoritusta kognitiivisissa testeissä, vaikka ne 
liittyivät kaksisuuntaiseen mielialahäiriöön. Tuloksista voidaan päätellä, että taudille 
altistavat variantit voivat olla edullisia jollekin toiselle ominaisuudelle. Löydökset 
myös selittävät, miksi ne ovat säilyneet valinnasta huolimatta. Näistä tuloksista 
voimme päätellä, että uni ja mieliala sekä aineenvaihdunta ovat kytkeytyneet jo 
perinnöllisellä, yksittäisten geenimuotojen tasolla toisiinsa.  
Unen kanssa yhteisvaikuttavien geenien toiminnan tunteminen on tärkeää 
sairauksien synnyn ymmärtämisen kannalta. Biologisten reittien kartoittaminen luo 
myös vahvan pohjan uusien lääkemolekyylien kehittämiselle.   
 
   
 
Avainsanat: uni, mielialahäiriöt, sydän- ja verisuonitaudit, genetiikka, SNP 
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1 Introduction 
Sleep is common to all animals. It has inspired both artists and scientists for 
centuries due to its mystical and enigmatic nature, and still despite considerable 
efforts of the scientific community, it is unknown why we sleep. Insufficient sleep 
has a large impact on public health and economy. Insufficient sleep or poor sleep 
quality are both risk factors and co-morbidities for psychiatric and cardiometabolic 
diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease, coronary 
heart disease and obesity (Cappuccio et al., 2010a, Cappuccio et al., 2010b). It has 
been estimated that poor sleep accounts for $1967 expenses in productivity per 
employee every year in USA alone (Rosekind et al., 2010). During the past three 
decades the mean sleep duration has decreased on estimate more than thirty minutes 
(Tune, 1968, Kronholm et al., 2008). At the same time, the prevalence of 
cardiometabolic diseases has steadily increased. Twin studies (Paunio et al., 2009, 
Watson et al., 2010), genome-wide RNA expression studies (Mackiewicz et al., 
2007) and genome-wide association studies (GWA study) (Ingelsson et al., 2010) 
have all pointed toward a genetic connection between sleep, metabolism and 
psychiatric diseases.  
During the past decade, the understanding of the human genome has evolved 
from solving the sequence of only a few individuals during the early days of the 
human genome project (Lander et al., 2001, Venter et al., 2001), into large scale 
genome-wide gene polymorphism mapping and involving over a hundred thousand 
study subjects or sequencing studies aiming at several thousand individuals (The 
1000 Genomes Project Consortium, 2010). The development of technology, 
statistical methods and above all understanding of the genomic landscape, have 
yielded tools that were not available before to study complex genetic traits, such as 
sleep. In several, especially cardiometabolic traits, this progress has resulted in an 
increasing amount of disease loci and given important new information on human 
physiology (Ingelsson et al., 2010, Teslovich et al.). The heritability of sleep 
duration is also substantial, 44% (Partinen et al., 1983). This is probably due to the 
strong heritability of electroencephaography (EEG) traits, which is over 96% (De 
Gennaro et al., 2008).  
Ten years ago, only a few genes and genetic variants for complex genetic traits 
such as sleep were known. In terms of sleep research, the genetic studies are needed 
to solve the molecular mechanisms in sleep regulation and the connection between 
sleep and comorbid diseases. In effect, studies on sleep duration, chronotype, sleep 
quality and EEG traits have now entered the phase of large-scale genetic studies 
based on GWA studies or genome-wide RNA expression studies. This thesis aims to 
use the traditional candidate gene approach as well as genome-wide tools combined 
with functional analysis to study the normal variation in sleep duration, 
Introduction 
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consequences of sleep loss and, finally, the connection between sleep and comorbid 
diseases in humans on a genetic level. 
 
Review of the Literature 
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2 Review of the Literature 
2.1 Genetic Architecture of Complex Traits 
2.1.1 DNA 
The human genome consists of roughly 3.2 billion base pairs (bp) of 
deoxyribonucleic acid (DNA) and it carries most of the information needed for 
inheritance. DNA is stored packed around histone molecules that support the 
structure. It is divided into chromosomes that are located in the nucleus of every 
cell. The structure of DNA is presented in Figure 1. DNA has two basic elements: a 
sugar phosphate backbone and a nucleo base which is attached to the sugar. The 
order of the bases converts the information in the form of genes. There are four 
common bases in DNA that form the DNA sequence: adenine (A), guanine (G), 
cytocine (C) and thymine (T). Most cells have DNA to store the information but 
RNA viruses rely on RNA for information storage as well as circulating red blood 
cells that only have RNA transcripts and protein products needed for cell function. 
Altogether, 22 autosomes and 2 sex chromosomes (X and Y) exist in humans and 
the genome is diploid in nature containing two copies of each chromosome, except 
for germ line cells that are haploid.  
 
 
Figure 1. DNA is packed in chromosomes (http://www.genome.com). DNA consists of a 
double helix made of deoxyribonucleic acid. The variable base region consists of 
adenine (A), thymine (T), cytosine (C) and guanine (G). A forms a base pair with 
T and C forms a pair with G. DNA is bent into a double helix. Histone molecules 
stabilize the structure and the DNA is packed in chromosomes. Chromosomes are 
located in the nucleus of the cell.  
Review of the Literature 
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All individuals are 99.9% identical based on their DNA sequence and thus only 
0.1% of the DNA sequence is responsible for genetic differences (Przeworski et al., 
2000, Reich et al., 2002). Most of the genetic variation in the DNA that affects the 
phenotype has been thought to be located in genes. The estimated number of genes 
in human the genome has come down from 100 000 to 20 000 (Carninci and 
Hayashizaki, 2007, Lander et al., 2001, Venter et al., 2001). Today it is thought that 
it is both the complex interplay between genes and networks formed by the genes 
rather than only the amount of specific gene products or individual genetic variants 
that affect the studied traits in humans (Chalancon et al., 2012). It was also recently 
discovered that most of the individual variants can have a functional role either in 
regulating chromatin structure, RNA transcription, histone modification or 
transcription factor binding, discussed below (Bernstein et al., 2012). 
 
2.1.1.1 Variation in DNA 
The 0.1% variation in the sequence can occur in several forms between individuals 
(Figure 2). Single nucleotide polymorphisms (SNPs) are one base pair differences 
between individuals in a given chromosomal location (locus). SNPs are usually bi-
allelic, meaning that two of the four different nucleotides can occur in a bi-allelic 
locus. A certain combination of SNP-alleles in one region forms a haplotype and 
variation can occur also at the haplotype level. Individuals with different haplotypes 
have a different set of SNP-alleles forming the haplotype (HapMapProject, 2005).  
The genomic DNA also contains repeat sequences of short nucleotide sequences 
that vary in length between individuals. These variable nucleotide tandem repeats 
(VNTR) are used for example in genetic fingerprinting and forensics, and can be 
further divided into several classes. The most common classes are microsatellites 
and minisatellites. Microsatellites contain short tandem repeats and short sequence 
repeats, whereas minisatellites have more than ten base pairs.  
Nucleotide sequence differences of more than 1kb at a given locus are called 
copy number variations (CNV) (Fredman et al., 2004, Iafrate et al., 2004, Sebat et 
al., 2004). In addition, there are five major forms of variation that can be used to 
categorize either SNPs or CNVs: 1) deletion, where the individual is missing a part 
of the genome 2) duplication, where there is an increased amount of copies of a 
given sequence 3) substitutions and in case of only CNVs 4) inversion, where the 
sequence of DNA is inverted and 5) translocation, where the DNA fragment is 
located or copied into a different region (Figure 2). Large CNVs are commonly 
found especially in cancers. Genome-wide studies have found these variants also 
contribute to other common complex diseases, especially in the field of psychiatric 
genetics (Kirov et al., 2012, Stefansson et al., 2008).  
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New genetic variants are constantly introduced to the human genome on average 
at the rate of 10-8 base pairs per generation (The 1000 Genomes Project Consortium, 
2010) and each individual carries approximately 250 to 300 loss-of-function variants 
(The 1000 Genomes Project Consortium, 2010). The genetic variations and new 
random mutations occurring even today have enabled the survival of the human race 
in evolution. 
 
Figure 2. Variation in DNA (http://www.genome.com). Variation in DNA can occur in 
small scale (Micro) where individual bases are changed into other bases or in large 
chromosomal scale (Macro) where several nucleotides or even chromosomal 
regions are mutated or differ between individuals. 
2.1.2 RNA Expression and Gene Networks – From Gene to Function 
All proteins in an organism are produced based on a genetic code. The coding 
sequence of DNA is first transcribed into an intermediate product, messenger RNA 
(mRNA) that is then used as a template for transfer RNA (tRNA), which adds a 
correct amino acid in the growing protein polypeptide chain thus translating the 
information into a protein (Figure 3). Proteins are then further modified with 
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posttranslational modifications and signal sequences that mark the destination for 
the proteins. DNA is similar in almost all cells in the body, except for white blood 
cells, where the DNA sequence in the regions encoding pathogen recognizing 
proteins is actively modified by adding or deleting nucleotides in order to create 
larger variability of receptors that can detect pathogens. Another exception is 
germline, which is haploid. The divergence in cellular phenotypes is mediated 
mainly through changes in the amount of enzymatically functional RNAs and 
proteins. Similarly, individual SNPs and differences in the genetic code mediate 
their effect on the phenotype largely due to differential gene expression and thus 
different amounts of produced proteins (Nica et al., 2010, Nicolae et al., 2010). The 
normal variation only rarely produces dysfunctional proteins but affects the 
magnitude of cellular and genetic responses to changes in the environment.  
 
Figure 3. Regulation from DNA to protein level (© Hanna Ollila). The DNA in the 
nucleus of a cell is first transcribed into mRNA, which is transported to the 
cytoplasm. The mRNA molecule is then used as a template for tRNA that adds 
new amino acids into the growing amino acid chain. Once the amino acid chain 
has been completed the new protein is synthesized. All these events are regulated 
and can have an effect on the phenotype. 
There are a number of elements in the DNA sequence that affect the magnitude 
and precision of the transcription. Promoter sequences, located typically upstream of 
the gene, contain binding sites for transcription factors and RNA polymerase that 
mediate the transcription of DNA to RNA. Transcription factors can modulate the 
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magnitude of expression either by enhancing the binding and transcription of RNA 
polymerase or repressing the transcription and binding of the polymerase. Several 
transcription factors have been identified for sleep regulation. These include the 
CLOCK and BMAL transcription factors that dimerize into molecular complex. 
This binds a basic helix-loop-helix (bHLH) transcription factor binding site on the 
promoter of their target genes and thereby helps to activate their transcription (Lee et 
al., 2001). 
In addition, the modifications of a DNA molecule can affect the magnitude of 
RNA expression. These covalent modifications are made onto the histone molecules 
supporting the structure or into the DNA itself and are called epigenetic 
modifications. The most studied forms of epigenetics are methylation and 
acetylation. The modifications in DNA are called epigenetic modifications since 
they do not affect the coding nucleotide sequence but the activity of the genes. 
Epigenetic modifications can also be inherited from one cell generation to the next 
(Henikoff and Shilatifard, 2011, Law and Jacobsen, 2010). Similarly, the density of 
DNA packing and the epigenetic modifications are related to the tissue specific 
expression of genes and may explain part of the difference of gene expression levels 
in the central nervous system and in the peripheral tissues. Epigenetic modifications 
are a way to react to the environment and change the activity of genes by making 
structural changes in the DNA without affecting the coding sequence (Kota and Feil, 
2010, Law and Jacobsen, 2010, Okano et al., 1999, Reik, 2007). In the field of 
psychiatric genetics for example, it has been shown that working in a stressful 
environment is related to lower methylation of serotonin transporter SLC6A4 and 
thus potentially higher expression levels (Alasaari J, 2012). Interestingly, a familial 
form of narcolepsy has been found to be caused by a mutation in gene encoding for 
DNA methylation transcription factor 1 (DNMT1). Such a mutation is likely to have 
a wide-range effect on overall methylation at the genome level (Devlin et al., 2010, 
Winkelmann et al., 2012).  
2.1.2.1 Transcriptional Networks 
The individual genes in an organism only rarely carry out their function alone but 
are linked together into pathways and networks where several genes have a joint 
effect on a biological function.  
Genes can be clustered in pathways based on their function, like metabolic 
pathways, signal transduction pathways or regulatory pathways. Joint efforts from 
Gene Ontology (Ashburner et al., 2000) and KEGG Consortiums (Kanehisa et al., 
2004) have clustered genes into the pathways based on their biological functions. 
Similarly, SNPs can be clustered into pathways based on the annotations that define 
either the closest gene or target gene of whose expression is affected by a SNP. An 
example of pathways relevant for human diseases is the signal transduction pathway 
NF-kB signalling cascade that has been shown to be important in autoimmune 
diseases, especially in Crohn’s disease. In this disease, aberrant integration of the 
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pro-inflammatory and anti-inflammatory cytokine pathways is partially responsible 
for disease progression (Abbott et al., 2004).  
Most genes or their protein products are integrated in the cells. Integrative 
networks can include both inhibitory and activating parts so that the sum of the 
network, such as the overall changes in the expression levels, is more precisely 
connected to the biological phenomena than the action of the individual proteins or 
pathways alone. Cells are fine-tuned to receive information from environmental 
challenges and responses by taking into account the availability of cellular 
resources. A single gene can be part of several networks. This makes it possible to 
integrate information in the network and create interactions between the pathways. 
Another benefit from networks is that they affect the biological responses by 
combining responses from two or more pathways (Ashburner et al., 2000). 
2.1.3 The Human Genome 
The beginning of the 21st century has been a success story for human genetic 
research. The sequence of the human genome was first elucidated by the Human 
Genome Project (HGP). The aim of the project was to characterize the DNA 
sequence of the human genome. The original genome was based on the sequence of 
four individuals, two males and two females, and was published by the HGP and by 
Celera, a commercial company, in 2001 (Lander et al., 2001, Venter et al., 2001).  
The HGP was completed in 2003, as well as the characterization and the 
publication of the single nucleotide polymorphisms and their allele frequencies in 
the dbSNP database, making it possible for independent researchers to access and 
use the genome data (International Human Genome Sequencing Consortium, 2004, 
Sachidanandam et al., 2001, Sherry et al., 2001).  
The next findings came in the form of haplotypes. It was shown that there is a 
high linkage disequilibrium (LD) in the human genome i.e. markers in the vicinity 
of each other are more often inherited together than what would be expected by 
chance (Pritchard and Przeworski, 2001). A few years later, the international 
HapMap project published the first haplotype map of the human genome (The 
International HapMap Consortium, 2005). The goal of the HapMap project was to 
determine the common patterns of DNA sequence variation in humans (The 
International HapMap Consortium, 2003). Altogether 3.1 million SNPs and their 
allele frequencies were characterized (Frazer et al., 2007, The International HapMap 
Consortium, 2005). The HapMap study sample comprised of individuals from four 
different populations and the main findings from this project were that the genome is 
organized into recombination hotspots that create LD blocks. Moreover, the 
haplotypes were found to be shared across different populations (The International 
HapMap Consortium, 2005, Jakobsson et al., 2008). Together these findings enabled 
a precise design of genotyping that is also utilized by the GWAS platforms today. 
This means that variation in a given region can be studied by genotyping only the 
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tagging SNPs (tagSNP). These tagSNPs and their haplotypes will provide 
information of all the common variation in the region even though the measured 
tagSNPs are only rarely the causative variants that associate with the trait (The 
International HapMap Consortium, 2005).  
A deeper coverage based on the sequencing of the human genome was provided 
in 2010 by the 1000 Genomes Project (1000 Genomes, 
http://www.1000genomes.org/) (The 1000 Genomes Project Consortium, 2010). The 
original goal of this project was to characterize genetic variation that is present in 
more than 1% of the population. The 1000 Genomes project was based on low 
coverage sequencing of the study participants from five different populations from 
West Africa, Europe, East Asia, South Asia and the Americas. The study expanded 
the understanding of the sequence variation of SNPs and CNVs in the human 
genome in large scale and also studied the rare variation in the genome at individual 
and population levels from five different populations. Altogether 15 million SNPs 
were discovered, of which, two thirds were already known by dbSNP. In addition, 1 
million short CNVs and 20,000 structural variations were discovered. The genetic 
variation was lowest near the transcription start site of the genes suggesting, that 
selection reduces variation at these sites. This finding supported the earlier 
hypothesis that genes are most vulnerable for large changes in the DNA sequence 
since they encode the functional proteins (The 1000 Genomes Project Consortium, 
2010).  
As the early breakthroughs in human genetics by HGP found, rather surprisingly, 
that most of the genome is non-coding DNA and that exons comprise only 1% of the 
genome (Venter et al., 2001), the rest of the genome was called simply “junk DNA”. 
For some time junk DNA was considered to have no or just minor biological 
relevance. However, the ENCODE Project (Encyclopedia of DNA Elements) aimed 
at characterizing functional elements in the DNA sequence. In September 2012 a 
number of roles with biological significance were found for the junk DNA by the 
ENCODE Project. The new studies found biological functions in regulation 
chromatin structure, RNA transcription, histone modification, or transcription factor 
binding for more than 80% of the genome (Bernstein et al., 2012). This also shed 
light on association studies as many of the SNPs that are known to affect biological 
traits are also located outside the protein coding sequence of DNA. Similarly the 
number of protein coding genes was estimated at 23,000–40,000 based on the 
original papers and has now come down closer to 20,000, suggesting that there is 
much more than just individual genes to look for in the genome (Carninci and 
Hayashizaki, 2007, Lander et al., 2001, Venter et al., 2001).  
Genetic variation can take place both between populations and within a 
population. Studies in population genetics have evidenced a larger within population 
variation than variation between populations. Even though most of the variation is 
neutral, some parts of the genome are under strong selection (Voight et al., 2006). 
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There are also a large amount of SNPs that show different allele frequencies in 
different populations or are population specific. It may be that those SNPs that differ 
between populations, could imply local adaptation (The 1000 Genomes Project 
Consortium, 2010). 
In the Finnish population, which is relatively isolated from the rest of the 
European populations, the amount of genetic variants is smaller and there is stronger 
LD between markers i.e. they are more likely to be inherited together. Nonetheless, 
there is quite large variation between different geographical regions within Finland 
(Jakkula et al. 2008).  
2.1.4 Complex Genetic Traits 
In polygenic traits many variants are thought to contribute to phenotypic variation. 
In these traits, a common marker, common disease view prevails. It is thought that a 
number of relatively common variants of over 1–5% frequency SNPs with low 
effect size contribute to the genetic component in common diseases. These variants 
would have such a low individual effect size that they would have remained in the 
population despite selection (Figure 4). Even though these variants have relatively 
small effect themselves, they present a significant effect when studying these 
variants in the scale of the population. This is due to the fact that many individuals 
carry the low effect risk variants that predispose to a disease or affect a trait (Risch 
and Merikangas, 1996). In contrast, disease markers with high effect on the trait 
would be under negative selection and thus become rarer (Lander, 1996, 
Chakravarti, 1999).  
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Figure 4. Common disease, common variant. In the common disease common variant 
hypothesis it is thought that the markers present in over 5% of the population 
account for phenotypic variation. These markers have low effect size (OR<2.0). In 
the rare variant hypothesis it is thought that rare variants present in less than 0.5% 
of the population with higher effect size contribute to the phenotypic variation 
(OR>2). In addition, variants with 0.5%–5% in the population can have 
intermediate effect on the phenotypic variation. Reprinted with permission. 
Manolio et al. Nature 2009.  
The rare variant hypothesis states that a large amount of rare population specific 
genetic variants with large effect size account for a larger part of genetic variation 
within a trait, and while the common variants only account for a minority of the 
variation (Gibson et al., 2012). Both common and rare variants are now thought to 
contribute to the variation in complex traits. In addition, variants present in 0.5%–
5% of the population can have intermediate effect on phenotypic variation.   
2.1.5 Methods for Studying the Genetic Component of a Disease 
Population genetic studies aim at finding the genetic background of common traits 
and diseases at the level of population. The first step in studying genetic traits is to 
show using family, twin or adoption studies that the trait has a genetic component 
that it is inherited. It should be noted that heritability estimates do not tell the 
number of genes or variants that associate with the trait but how much of the 
variation is explained by genetic factors. The second step of analysis is to elucidate 
which genetic markers associate with the trait. 
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2.1.5.1 Twin Studies 
Twin studies can dissect the variation caused by genetic factors compared to 
environmental factors, since monozygotic twins (MZ) share nearly 100% the same 
DNA, while dizygotic twins (DZ) as well as siblings, share 50%. The environment 
of twins is also more similar than that of normal siblings since they develop at the 
same time in the uterus. As genes often interact with the environment, adoption 
studies are also valuable for geneticists and can distinguish the effect of postnatal 
environmental factors more precisely. In classical twin studies the covariance for a 
trait in DZ twins is compared to the covariance in MZ twins. Genes can have an 
effect on a studied trait together with the environment. Such interactions can be 
studied using gene environment interaction models. In classical twin studies it is 
estimated that these interactions are absent. 
2.1.5.2 Family Studies and Linkage Studies 
Family studies can be used for estimating the model of inheritance: for example 
whether a disease is inherited as a dominant or recessive trait. As most of the 
common complex traits are a sum of several genetic factors, they are polygenic. The 
individual genetic variants have their own model of inheritance. For monogenic 
traits, only one gene is necessary but also sufficient to cause a disease. However, 
even for monogenic traits there is variability in the phenotype. The proportion of 
affected individuals compared to all individuals carrying a disease variant is called 
penetrance. For variants with high penetrance and one contributing genetic variant, 
it is usually relatively feasible to define the model of heritability in contrast to 
complex polygenic diseases.  
Families can be studied using linkage analysis, where the segregation of a marker 
is estimated together with the disease. However, linkage analysis requires the 
individual variants to have relatively large effect size (Risch and Merikangas, 1996). 
Normally, association analysis is used to detect low effect variants in unrelated 
individuals, but it can also be applied to study relatives. 
In addition to the diseases themselves, heritable traits named endophenotypes can 
be used in the search for the genetic background of a psychiatric trait, such as 
cognitive performance in bipolar disorder or schizophrenia (Clark et al., 2005, 
Lenox et al., 2002). These typically quantitative traits can also be measured in 
unaffected family members. They are “measurable components unseen by the 
unaided eye along the pathway between disease and distal genotype” (Gottesman 
and Gould, 2003). Endophenotypes are inherited together with disease phenotypes 
and can be regarded as latent liability to the disease (Lenzenweger, 1999). 
Endophenotypes can be used to study the unaffected relatives that may carry some 
of the same predisposing variants common to the disease and the endophenotype. 
Including unaffected individuals with endophenotypes increases the sample size and 
thus power. It is thought that disease variants for some psychiatric traits remain in 
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the normal population due to the beneficial effects and that only accumulation of 
many variants will predispose to these complex diseases.  
2.1.5.3 Association 
Behind association studies there is a hypothesis that the studied marker is in high LD 
with the causative variant. Association analysis is used in case-control studies and 
cross-sectional population studies. It tests whether a variant has a different 
frequency in cases compared to controls. In case of a quantitative trait, it is 
estimated if the variant is becoming more frequent toward either end of the scale.  
Logistic regression models are used for dichotomous traits while linear 
regression models are mostly used for quantitative traits. For practical reasons the 
model of inheritance in genome-wide and candidate gene studies for a single risk 
variant are usually estimated to be additive with no genetic interactions. Where 
cross-sectional studies can detect associations and risks between a marker and a 
trait, prospective studies can find causal relationships between them. Additional 
study settings include experimental settings performed in controlled environments or 
requiring an intervention. Experimental studies are abundantly used in sleep 
research where for some of the traits, like polysomnography, overnight recordings 
are needed. 
 
2.1.5.4 Genome-wide Association 
Association analysis in a genome-wide scale was made possible by HGP. In 
addition, the annotation of SNPs and their LD structure by HapMap and dbSNP 
projects made it feasible to design SNP panels that covered most of the variation in 
the genome. The current methodology of complex genetic traits relies largely on 
high-resolution SNP panels containing up to approximately one million SNPs. The 
main advantage of GWA studies is that it is hypothesis-free, i.e. no prior knowledge 
of gene functions is required.  In contrast, traditional candidate gene studies are 
hypothesis-based. Stringent criteria for significance threshold in genome wide 
studies are necessary since a large number of tests are performed. The current 
significance threshold for a GWAS is P<5*10-8.  
GWA studies have also found a large number of common variants for metabolic 
traits (Ingelsson et al., 2010) whereas by the end of August 2012, only one genome-
wide significant (P<5*10-8) variant was characterized for sleep duration. One of the 
reasons why GWA studies have captured common variants more than rare variants 
is simply due to the fact that the platforms are designed to contain common variants 
that are thus better presented in current genotyping platforms. The elucidation of 
rare genetic variants will require larger sequencing efforts, customized GWA study 
platforms or high-quality imputation of rare markers that are only starting to emerge 
in the field of genetics. 
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Since 2005 when the first GWA studies were published, our understanding of the 
etiology of complex genetic traits has grown significantly. On top of the GWAS 
platforms, the 1000 Genomes and HapMap Project data enable the assigning of 
genotypes (imputation) of an additional 8 to 32 million SNPs (The 1000 Genomes 
Project Consortium, 2010, The international HapMap Consortium, 2005).  
Exome sequencing and whole genome sequencing studies have now started to 
elucidate the role of the rare genetic variants for example in type 2 diabetes in 
MTNR1B (Bonnefond et al., 2012) but also in the field of sleep research. One study 
described a variation in the circadian pacemaker gene DEC2 in familial short 
sleepers, whereas another found variation in familial narcolepsy with DNMT1 (He et 
al., 2009, Winkelmann et al., 2012). 
2.1.6 Missing Heritability 
Even though GWA studies have been successful in finding genetic polymorphisms 
for several traits, the current findings only explain a fraction of the total heritability 
of a trait. The unexplained part of heritability by currently known markers is referred 
to as missing heritability (Maher, 2008). There are several factors that may explain 
why all of the variants are not discovered. On the first hand, the current GWAS 
platforms are concentrated on common variation between individuals. It may be that 
there are rare variants, which explain part of the missing heritability that are not 
captured by the current methods. These variants are too rare to be captured by GWA 
studies but do not have sufficiently large effect size to be found with traditional 
linkage analyses.  
On the other hand, heritability estimates do not take into account interaction, 
epistasis or gene networks. This means that current heritability estimates may 
overestimate the number of variants that are expected to be found for each trait (Zuk 
et al., 2012). It has also been shown that genes that form pathways explain a larger 
part of the heritability when studied as pathways and less of the heritability when 
studied as single variants alone. Thus, the whole network has a larger effect than the 
sum of the individual variants alone. Others have suggested that the heritability 
could reside outside SNPs either in the epigenetic regulation of diseases or in other 
polymorphisms, such as CNVs or repeat polymorphisms (Hannan, 2010). 
2.1.7 Challenges in the Analyses of Complex Traits 
Several factors can create challenges in analyzing genetic data and create variation 
either at the genetic or phenotypic level. First, only a few phenotypes can be 
measured without any bias. Most of the psychiatric traits are measured using 
questionnaires or diagnosis by a physician, which both creates subjective 
measurements and may thus bias the phenotype. For some traits, such as sleep 
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measured with polysomnography, there is a way to measure the trait objectively. 
However, these measures cannot be done in large scale currently due to time and 
cost aspects. One solution is to verify the statistically most significant findings in 
experimental settings, such as in animal models, and characterize their biological 
role in general in more detail (Dermitzakis, 2012). 
Most complex diseases have a variety of symptoms that can vary in severity, 
making it more challenging to decide whether a person should be defined as a case 
or a control. Similarly, differences between populations can be substantial. The scale 
of body mass index (BMI) is different for individuals from Europe and individuals 
from Asia. For example, the cut off BMI values for overweight are 30 on the 
Western scale but 27.5 for the Asian scale. 
Phenotypes from biologically separate traits can overlap or display as 
phenocopies. These phenocopies have a different genetic composition, however. On 
the other hand, individual genotypes may have different effects depending on the 
environment; different environments produce different phenotypes. Similarly, 
genotypes may interact together creating different phenotypes. Maybe the most 
dramatic evidence of such interaction is fatal familial insomnia and Creutzfeld Jakob 
disease, where one SNP D178N at the coding region of the PrP gene often causes 
the disease but the severity of the phenotype and the progression of either disease is 
dependent on the other SNPs in the gene (Capellari et al., 2011). SNPs can thus have 
different effects for different diseases. Genetic effects may also be beneficial for one 
and deleterious for another trait. Such variants are known for example for 
autoimmune diseases where a variant in PTPN2 increases the risk of type 1 diabetes 
and rheumatoid arthritis, but is protective for Chrohn’s disease (Barrett et al., 2008, 
Plenge, 2008). 
Population stratification can create variation in the analysis. For example, there is 
relatively large variation between geographical regions in Finland (Jakkula et al., 
2008). Adjusting for population stratification based on geographic location and 
adjusting for genetic principal components largely reduces the variation due to 
geographic differences (Jakkula et al., 2008, The 1000 Genomes Project 
Consortium, 2010).  
The studied variant only rarely is in complete LD with the causative variant and 
the used platform may not contain any variants in the causative region. However, 
haplotype analysis and exome sequencing can overcome some of these challenges 
by introducing more information on the studied locus. The search for common 
variants with low effect size or rare variants with high effect size also requires large 
sample size and sophisticated statistical methods in order to have sufficient power to 
detect the associating variants (Liu and Leal, 2010).  
Complex traits by definition are affected by more than one gene and it is possible 
that there is genetic interaction between the markers or between a marker and the 
environment. The possibility of genetic interaction is normally not taken into 
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account in heritability estimates, which may eventually lead to overestimation of the 
amount of variants that contribute to a trait (Zuk et al., 2012). The gene-environment 
interaction studies as well as gene-gene interaction studies also need large sample 
sets in order to overcome multiple testing issues (Wang and Zhao, 2003, Smith and 
Day, 1984).  
 
2.1.8 Association Analysis and Biological Function 
For several complex genetic traits, such as blood lipid levels or T2DM, many of the 
common genetic variants are now known (Kettunen et al., 2012, Teslovich et al., 
2010). It is, however, even more important to know why some changes at the level 
of DNA are related to a disease and how the changes in the phenotype are caused. In 
effect, the next step is to connect the individual variants with biological function. 
More precisely, what the consequences of having a certain variant are. One 
possibility is to look for the gene expression of nearby genes in relation to variants 
that associate with a trait (Cheung et al., 2005, Goring et al., 2007). These 
expression quantitative trait loci (eQTL) provide the information whether a 
polymorphism is related to changes in gene expression that might affect the trait. 
Similarly, effects of SNPs can be studied together with epigenetic changes (Kilpinen 
et al., 2012).  
One method is to characterize the effects of associating variants or nearby genes 
in animal models. This approach has been used successfully in sleep research where 
a variant in DEC2 was discovered in a family with short sleep duration. The gene 
was further characterized in an animal model. The mice deficient for DEC2 did not 
show difference in their sleep duration. However, shorter sleep duration was seen 
only when the same mutation was introduced to the mice (He et al., 2009).  
It would always be necessary to relate functional studies back to human 
physiology. One possibility is to perform studies in relation to human phenotypes in 
a controlled environment. In the field of sleep research such approaches have been 
applied in sleep restriction models. These studies have characterized a VNTR in 
PER3 that associates with sleep intensity and cognitive performance after sleep loss 
(Viola et al., 2007, Groeger et al., 2008) as well as with diurnal preference (Archer 
et al., 2003).   
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2.2 Sleep and Circadian Rhythm 
2.2.1 What is Sleep? 
Sleep is characterized by reduced consciousness, prolonged reaction time, 
immobility, and declined posture. So far all animals are known to sleep. Circadian 
processes in turn regulate the timing of sleep, as well as feeding and several other 
physiological processes such as daily rhythms in temperature, hormonal signals, 
performance and mood, illustrated in Figure 5. Both sleep and circadian rhythms are 
tightly regulated. However, it is not known why we sleep even though we spend a 
substantial amount of time, a third of our lives sleeping. Several hypotheses for the 
function of sleep exist, however, and many of those agree that sleep is restorative or 
they link sufficient sleep with conservation of energy or with brain plasticity (Cirelli 
and Tononi, 2008). 
 
Figure 5. The circadian variation in physiology (Wikimedia commons). Mood and body 
functions show circadian and circannual rhythms. Highest testosterone and 
alertness levels occur in the morning whereas best physiological performance 
takes place in the afternoon. Desynchrony in circadian rhythms is related to 
diseases.  
2.2.2 Measuring Sleep 
In humans sleep is usually measured in sleep clinics with polysomnography (PSG), 
which comprises of signals from electroencephalogram (EEG), electro-oculography 
(EOG) and electromyography (EMG). Different sleep stages can then be scored 
based on their polysomnographic fingerprint. Sleep can also be assessed with 
movement detectors, actigraphy, or with questionnaires. 
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2.2.2.1 Polysomnography 
Human sleep consists of periods of wake (W) and two distinct types of sleep: rapid 
eye movement (REM) that is often marked in sleep scoring with R and nonREM 
sleep (NREM) that can be further divided into three stages N1-N3 based on the PSG 
signals. N1 reflects the lightest and N3 the deepest NREM sleep stage (Iber, 2007). 
The sleep stages can be characterized based on their PSG profile by interpreting 
EEG, EMG and EOG signals together. The PSG of REM sleep is characterized by 
muscle atonia seen in EMG. The characteristics of REM sleep in EEG are similar to 
waking EEG with both high and low amplitude signals. Most dreams occur also in 
REM sleep but some can also be present in NREM sleep. NREM sleep has high 
voltage and low frequency EEG activity without muscle atonia and especially N3 is 
characterized by deep slow wave sleep (SWS) delta waves that reflect sleep density. 
NREM and REM sleep occur cyclically during the night so that light sleep is 
followed by deeper sleep, and finally a REM sleep episode (Rechtschaffen A. 1968).  
Usually, the first part of the night in humans is abundant in NREM, especially in 
SWS sleep, whereas the proportional amount of REM sleep per sleep cycle increases 
toward the end of the sleep period (Rechtschaffen and Kales, 1968). In addition, the 
frequency of the EEG waves can be studied. The delta 0.5–4Hz frequencies 
correspond well with deep stage 3 sleep, slow wave sleep (SWS), and are referred to 
as slow wave activity (SWA). The other frequencies are theta 4–8Hz, alpha 8–13Hz 
and beta >13Hz. The delta and theta frequencies have been connected with sleep 
homeostasis as the SWA delta power can be used as a homeostatic marker for 
estimating the need for sleep, i.e. sleep pressure (Brunner et al., 1993). Delta waves 
have also been related to memory processing during sleep, meaning that activity 
bursts in SWA may strengthen the connections between synapses (Hanlon et al., 
2011). 
In addition to sleep EEG, the waking EEG can also be used for studying sleep. 
The waking EEG theta activity can be used as a marker for the build-up of 
sleepiness (sleep pressure) both in rats and humans (Brunner et al., 1993, Finelli et 
al., 2000, Vyazovskiy and Tobler, 2005). More generally, theta has been related to 
attention, memory processing and the plasticity of the brain. A confounding factor in 
human EEG is age. Human EEG changes over age so that the amounts of SWS, 
REM sleep, and N1 and N2 sleep decrease with age, whereas the number of 
awakenings after sleep onset increases (Ohayon et al., 2004).  
2.2.2.2 Actigraphy and Questionnaires 
During sleep cycles individuals show differences in the amount of movement. Sleep 
and circadian rhythm can be measured with motor activity using a watch-like device 
called an actigraph. The actigraph detects movement and is thus able to define for 
example sleep duration, even though differentiating between the sleep stages is not 
possible based on actigraphy alone. However, sleep time measured with actigraphy 
shows over 90% correlation with PSG scoring (Ancoli-Israel et al., 2003). Other 
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studies have shown that sleep wake cycle and sleep duration are well scored with 
actigraphy alone (over 0.9 correlation with PSG) but that more detailed analysis 
such as sleep onset or sleep efficiency were hard to measure (Reid and Dawson, 
1999). Measurements with actigraphy are significantly cheaper compared to full 
PSG recordings and can be analyzed automatically. Actigraphs are ideal for research 
use due to their low cost and the fact that they can be worn for several weeks. In 
clinical use many sleep disorders can be detected without overnight recordings at the 
clinic by using actigraphy in the patient or study subject’s home. The American 
Academy of Sleep Medicine does not, however, recommend using actigraphy 
instead of PSG recordings in diagnosis or in management of sleep disorders as many 
sleep disorders cannot be diagnosed by movement signal alone. Nonetheless, they 
suggest that it can be used for assessing specific sleep disorders such as insomnia, 
excessive sleepiness and circadian rhythm sleep disorders.  
An alternative method for measuring sleep is to use questionnaires or single 
questions that are often included in population cohorts. A number of scales have 
been developed for measuring different sleep parameters such as sleepiness 
(Epworth sleepiness scale), insomnia, chronotype (morningness-eveningness 
questionnaire), circannual rhythms (global seasonality pattern assessment 
questionnaire) and sleep duration and quality questionnaires like the Pittsburgh sleep 
quality questionnaire, (Buysse et al., 1989, Horne and Ostberg, 1976, Johns, 1991, 
Rosenthal, 1984). Questions about sleep are also part of many questionnaires 
assessing psychiatric diseases such as depression in the Beck depression inventory 
(Beck et al., 1961). Sleep questionnaires are useful for large-scale studies but may 
present a subjective bias in the measurement. However, for some sleep disorders the 
subjective measurements are more relevant than the objective ones. For example in 
insomnia, patients often report daytime sleepiness and “not being able to sleep 
during the night” even though PSG findings show sleep during the night. However, 
time spent in SWS is often reduced in insomniacs (Dorsey and Bootzin, 1997, 
Edinger et al., 2004). Choosing the correct method for studying sleep is thus 
important and often a compromise between time and money consuming PSG 
measurements, compared to relatively inexpensive questionnaire based studies. 
Combining several methods may also provide a more thorough understanding of 
sleep and the studied phenotypes. 
2.2.3 Neuroendocrine Regulation of Sleep and Circadian Rhythms 
2.2.3.1 Neurological and Chemical Correlates of Sleep and Wake 
Sleep and wake are regulated by the wake-promoting and wake-inhibiting 
neurotransmitters that together form a flip-flop switch, providing a rapid transition 
from wake stage to sleep stage. The switch is controlled by wake-promoting and 
sleep-promoting neurotransmitters and by the circadian input that can reduce the 
sleep drive reviewed in (Stenberg, 2007). The wake-promoting neurons in the 
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ascending reticular arousal system (ARAS) promote cortical arousal via two 
neuronal pathways: the dorsal route through the thalamus, and a ventral route 
through the hypothalamus and basal forebrain, which in addition receives activating 
inputs from orexinergic and melanin concentrating hormone (MCH) containing 
neurons. In more detail, the ARAS contains the noradrenergic neurons in the 
ventrolateral medulla and locus coeruleus, cholinergic neurons in the laterodorsal 
tegmental nuclei and in the pedunculopontine nuclei (Hallanger et al., 1987), 
serotonergic neurons in the raphe nuclei, dopaminergic neurons in the ventral 
periaqueductal gray matter and histaminergic neurons of the tuberomammilary 
nucleus. In addition, orexin and MCH neurons from the lateral hypothalamus and 
GABAergic neurons from the basal forebrain contribute to the arousal signal.  
The main sleep-promoting network is located at the ventrolateral preoptic 
nucleus VLPO, which has neuronal projections with inhibitory GABA and galanin 
neurotransmitters that project to the nuclei involved in ARAS (Fuller et al., 2006). 
These inhibitory networks are active during sleep, repressing the ARAS (Pace-
Schott and Hobson, 2002, Saper et al., 2001). Normally, transition stages between 
wake and sleep do not occur. However, occasional unexpected transitions during 
drowsy driving or napping can take place. Similarly, sleep disorders can arise when 
some of the flip-flop switch components are defective. An example of this is 
narcolepsy where the wake-promoting orexinergic signals are not present (Lin et al., 
1999, Nishino et al., 2000), leading to increased sleepiness during the day and 
fragmentation of sleep. Another example is REM sleep behaviour disorder where 
dreams are acted out (Schenck et al., 1986). 
2.2.4 Lipid and Carbohydrate Metabolism in the Brain 
The metabolic rate in the brain is high as it consumes 20% of total body oxygen, 
receives 15% of the cardiac output and uses 25% of the glucose (Zauner et al., 
2002). The energy demands of the brain are however reduced in sleep by 44% in the 
cerebral metabolic rate of glucose and 25% in O2 (Madsen and Vorstrup, 1991, 
Maquet, 1995). Deviations in energy metabolism can have a large impact on brain 
functioning as the brain actively regulates the homeostatic energy balance of the 
body. One function of sleep has also been suggested to be the restoration of the 
brain’s energy stores (Benington and Heller, 1995). 
2.2.4.1 Sensing Energy Metabolites in the Brain 
The major source of energy in the brain is glucose and its levels in the bloodstream 
are tightly controlled in order to keep blood glucose stable. The brain plays an 
important role in regulating fatty acid levels and body weight as well. This 
regulation is done in order to prevent hypoglycaemia as a fall in blood glucose levels 
could have detrimental effects on brain functioning. The main site in the brain for 
regulating glucose homeostasis is the hypothalamus, which combines information 
from the peripheral glucose sensors and circulating leptin and ghrelin levels and 
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from other brain regions that receive signals from the peripheral tissues. The 
hypothalamic neurons activate sympathetic and parasympathetic neurons that 
regulate glucagon and insulin secretion (Thorens, 2011). The brain can detect at 
least insulin, leptin, glucagon-like peptide 1 and 2, and ghrelin. Besides direct 
neuronal connections to the pancreas, a negative feedback loop regulates appetite 
and glucose production that is sensed and modified by insulin signaling in the 
hypothalamus (Caspi et al., 2007, Schwartz and Porte, 2005). In addition, the central 
administration of insulin inhibits food intake (Air et al., 2002). Similarly, the brain 
senses circulating energy carriers like glucose (Burcelin et al., 2000, Pocai et al., 
2005) and fatty acids (Obici et al., 2002). The communication is bidirectional as the 
fat tissue sends feedback hormones to the brain after taking in glucose or fatty acids. 
These include cytokines like TNFalpha, IL-1b, IL-6 and leptin, which inhibit food 
intake (Ahima and Flier, 2000). Interestingly, the same cytokines and leptin are 
known to increase after sleep restriction (Irwin et al., 2006, Spiegel et al., 2004a, 
Spiegel et al., 1999, van Leeuwen et al., 2009). 
2.2.5 Metabolic Control of Sleep 
Increase in local neuronal activity during waking increases neuronal energy 
consumption (Attwell and Laughlin, 2001) and is dependent on the timing, duration 
and location of the activity (Sokoloff, 1977). Increased neuronal activity is related to 
higher excitatory glutamatergic neurotransmission, which requires energy (Attwell 
and Gibb, 2005). Glucose transported via the circulation and subsequently ATP 
hydrolysis via glycolysis followed by oxidative phosphorylation is the main energy 
source for the brain to cover increased energy needs. In addition to glucose, lactate 
has been suggested to function as an energy source for the brain during increased 
activity (Pellerin et al., 2007, Pellerin and Magistretti, 1994). 
2.2.5.1 Adenosine 
When ATP demands are greater than the production of ATP, adenosine starts to 
accumulate in the extracellular space. Adenosine is an end product of ATP that can 
inhibit neuronal firing and induce sleep. It can thus protect neurons from running out 
of energy and from excessive firing (Dunwiddie and Masino, 2001, Latini and 
Pedata, 2001, Porkka-Heiskanen et al., 2002). An overview of the genes related to 
adenosine metabolism is presented in Figure 6. In short, adenosine binds G-protein 
coupled receptors A1, A2A, A2B and A3. The effects of adenosine on sleep are 
largely mediated through A1 and A2A receptors and the binding of adenosine to A1 
receptors, which inhibits the influx of calcium and glutamatergic signaling (Kocsis 
et al., 1984, Rebola et al., 2005) and induces the transcriptional activation through 
NF-kB mediated signaling (Basheer et al., 2001). Cellular and extracellular levels of 
adenosine are mediated through ENT and CNT transporters, which shuffle 
adenosine between these compartments and cellular organelles. Another source of 
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adenosine both inside and outside the cells is synthesis from ATP (Porkka-
Heiskanen and Kalinchuk, 2011). 
 
2.2.5.2 Hormones 
Human and murine EEG studies have been efficacious in studying the connection 
between sleep and other physiological processes, especially energy metabolism and 
endocrine functions that are related to changes in vigilance states and in sleep stages. 
SWS has a role in growth hormone (GH) secretion. GH secretion is controlled by 
sleep homeostat and increased in the first SWS episode (Van Cauter and Plat, 1996). 
Sleep also correlates with prolactin secretion. Even naps increase prolactin secretion 
(Van Cauter and Refetoff, 1985). Interestingly, sleep homeostasis and the duration 
of SWS also correlate with prolactin secretion (Linkowski et al., 1998). 
Furthermore, SWS has been shown to inhibit tyroid stimulating hormone and 
cortisol release (Follenius et al., 1992, Goichot et al., 1992). In addition, NREM 
sleep decreases heart rate (HR), blood pressure (BP) and vasoconstrictor tone 
reducing sympathetic nervous activity and increasing parasympathetic activity 
(Burgess et al., 2004, Somers et al., 1993, Van de Borne et al., 1994).  
 
Figure 6. Adenosine metabolism (© Hanna Ollila). Adenosine is the end product of ATP 
hydrolysis. The ENT and CNT transporters shuffle adenosine between cellular 
compartments and between extracellular and intra cellular space. SAH hydrolase 
catalyses the hydrolysis of SAH to adenosine (and back) whereas ADA catalyses 
irreversible deamination of adenosine to inosine.  
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2.2.6 Homeostatic and Circadian Control of Sleep 
Sleep is regulated by two independent but interacting processes. The timing of sleep 
is regulated by a circadian process (process C) over 24 hours, whereas the intensity 
and duration of sleep is regulated by a homeostatic process (process S) (Borbely, 
1982), shown in Figure 7. 
 
Figure 7. Homeostatic and circadian rhythm. Sleep is regulated by a circadian, daily 
rhythm (depicted in the figure as C), which has a self-sustained synchronous 
rhythm. The homeostatic component (depicted as S) regulates the response to prior 
waking, defining the pressure of need to sleep. Modified from Borbely et al., 1982. 
Figure created by Janneke Zant (http://urn.fi/URN:ISBN:978-952-10-8412-6). 
Reprinted with permission. 
The circadian process C is not dependent of prior waking but it oscillates within 
24 hours creating a circadian (daily) rhythm. It is generated by the master circadian 
clock that is located in the suprachiasmatic nucleus (SCN) in the hypothalamus in 
mammals. This self-sustained circadian rhythm entrains the cells and internal 
physiological processes, such as sleep, energy metabolism, temperature rhythm and 
cell division in the whole body (Tu et al., 2005, Buhr et al., 2010). The circadian 
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rhythm is synchronized primarily by light even though other synchronizers 
(zeitgebers) with a milder effect such as food or exercise, affect the rhythm (Foster 
and Hankins, 2002, Berson et al., 2002, Lax et al., 1998, Lax et al., 1999, Moore et 
al., 2002). The photic input is detected by specialized retinal ganglion cells 
containing melanopsin and conveyed via the retinohypothalamic tract to the SCN 
(Gooley et al., 2001, Provencio et al., 1998). The neurons projecting from SCN to 
the pituitary axes control the hormonal regulation of the circadian rhythm, whereas 
the neurons that project to the autonomic nervous system are related to neuronal 
control (Buijs et al., 2003). 
In contrast, the homeostatic control of sleep is largely dependent on the duration 
of prior waking so that extended wakefulness is followed by extended sleep, called 
recovery sleep (Borbely, 1982). In recovery sleep, especially the amount of EEG 
slow waves are increased and SWA can be used as a marker of sleep pressure or 
sleep intensity (Borbely, 1982, Borbely et al., 1981, Rosenberg et al., 1976). The 
homeostatic process thus regulates sleep need by recording the need for rest as sleep 
pressure that increases during waking and decreases during sleep. However, the 
homeostatic and circadian processes are connected, and in order to stay awake 
during the day the circadian alertness is increased to oppose the increasing sleep 
pressure. Similarly, during the night when sleep pressure decreases, the circadian 
sleep factor increases, and sleep is maintained (Dijk and Czeisler, 1995). 
 
2.2.7 Regulation of the Circadian Rhythm 
Clock genes are regulators of the circadian rhythm in cells and form a self-sustained 
molecular oscillator. They are located in the cells of SCN but also in many other 
tissues, such as the lungs, skeletal muscles, the pancreas and the liver, all of which 
contain pacemakers (Balsalobre et al., 1998, Sadacca et al., Yamazaki et al., 2000). 
The pacemaker genes are bHLH transcription factors that form feedback loops with 
positive (CLOCK, NPAS2, BMAL1, BMAL2) and negative regulators of the clock 
(CRY1, CRY2, PER1, PER2 and PER3). CLOCK and NPAS2 are capable of 
dimerizing with BMAL1 or BMAL2 and forming heterodimers. This transcriptional 
complex activates a number of genes with the E-box binding site such as CRY and 
PER proteins and DEC1 and DEC2, RORA, PPARa, RXRa and Rev-erbα. The 
negative regulators CRY and PER proteins dimerize and are transported back to the 
nucleus where they repress BMAL and CLOCK transcription and thus regulate their 
own expression by forming a negative feedback loop, reviewed in (Lee et al., 2001). 
Cytoplasmic levels of CRY and PER proteins are regulated by Casein kinase Ie that 
phosphorylates the proteins for degradation (Price et al., 1998). RORA and PPARα 
can directly bind and activate BMAL expression whereas Rev-erbα represses the 
CLOCK-BMAL complex (Liu et al., 2008). In contrast to genes in circadian sleep 
regulation, the genes regulating sleep homeostasis are largely unknown. 
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Circadian pacemakers have an important role also outside the brain in timing 
cellular and metabolic processes. Problems in synchronizing the peripheral tissues to 
the correct time may be dependent on at least two factors. First, the lower amplitude 
of an oscillator, such as poor melatonin rhythm, insulin resistance, irregular 
mealtimes or blindness, can have a weaker effect on keeping the target tissue in 
correct time. Second, environmental effects that cause desynchrony, such as jet lag 
or shift work, can desynchronize the central circadian clock in SCN. In addition, 
genetic differences in the clock genes can have an effect on the peripheral or central 
oscillators (Bass and Takahashi, 2010). 
 
2.2.7.1 Melatonin 
Melatonin is a hormone that shows high levels of circadian variation. Its levels are 
high during the night and low during the day as it is quickly degraded after light 
input (Brainard et al., 2001). It is thus considered a circadian hormone. The 
secretion of melatonin is under the control of SCN and it is secreted from the pineal 
gland even though other tissues such as leucocytes, enterocytes and retinal cells are, 
to a smaller extent, capable of producing melatonin (Lerner et al., 1960). The exact 
physiological role of melatonin in humans is unknown. In other animals it is the key 
signal that regulates annual reproductive rhythms as it signals the length of the day 
(Yoshimura, 2010). The signal transduction of melatonin is mediated by two 
receptors: G-protein coupled melatonin receptor 1 A (MTNR1A) and B (MTNR1B). 
The signal transduction ultimately leads to an increase in cyclic GMP and a decrease 
in cyclic AMP levels in the cytoplasm and the activation of the AKT/GSK3B-
pathway (Shieh et al., 2009). 
Melatonin has recently been linked with insulin signaling and T2DM, both at the 
physiological (Nogueira et al., 2011) as well as the genetic level (Ingelsson et al., 
2010). Melatonin has been shown to have an inhibitory effect on insulin secretion 
under normal conditions via the melatonin receptors (Lyssenko et al., 2009, Staiger 
et al., 2008, Muhlbauer et al., 2012).  
2.2.8 Why Do We Sleep? 
One of the major hypotheses suggests that sleep balances brain energy stores, 
especially in the form of glycogen in the brain that is consumed during waking 
(Benington and Heller, 1995). This theory is supported by observations in increased 
end metabolites after sleep deprivation in the brain. In addition, the homeostatic 
sleep factor adenosine is an end product of ATP metabolism, which links energy 
expenditure and energy homeostasis directly with sleep homeostasis (Porkka-
Heiskanen et al., 1997). Other theories have proposed that being asleep during the 
night helps to avoid nocturnal animals that could have, once, during human 
evolution, posed a threat, and vice versa. A third hypothesis links sleep with 
memory consolidation and synaptic plasticity. In more detail, this theory suggests 
Review of the Literature 
 
THL — Research 96/2013 44 Genetics of Sleep 
 
that sleep is needed to establish synaptic homeostasis after waking. Sleep 
deprivation studies have indeed shown that insufficient sleep reduces learning 
capacity and that sleep is needed for strengthening connections between synapses 
(Bushey et al., 2011, Hanlon et al., Yoo et al., 2007). 
2.2.9 Sleep Duration – How Much Sleep Do We Need 
Normal sleep duration is between 7 to 8 hours 
per day as estimated by the Health 2000 study in 
Finland, with a mean of 7.51 hours (Kronholm 
et al., 2006) or from the National Health 
Interview survey from the United States 
collected on 1990 with a mean of 7.28 hours 
(USA Census Bureau). There is a strong gender 
effect on sleep duration, as females sleep 0.23 
hours more in average than men (Kronholm et 
al., 2006). Although objective sleep duration has 
been shown to decrease with age (Ohayon et al., 2004), population-based studies 
from Finland have shown a U-shaped relationship between self-reported sleep 
duration and age which may reflect either changes in sleep architecture over life 
time or co-morbidities that increase with older age and would thus increase sleep 
duration (Kronholm et al., 2006).  
Several factors can have an effect on sleep duration in addition to age and 
gender. First, sleep homeostasis regulates sleep duration as sleep loss increases sleep 
duration the following recovery night (Borbely, 1982). Second, the circadian rhythm 
has an effect on sleep duration (Akerstedt and Gillberg, 1981) and melatonin can 
both deepen and initiate sleep (Zhdanova and Wurtman, 1997). Third, lower 
socioeconomic position is associated with shorter sleep duration (Stamatakis et al., 
2007). Fourth, psychological and psychosocial factors have a strong effect on sleep 
duration. Short sleep and sleep disturbances are more common in individuals 
suffering from major depression (Riemann et al., 2001), and loneliness or stress 
(Akerstedt et al., 2007, Cacioppo et al., 2002). Fifth, race and ethnicity have an 
effect on sleep duration. Sometimes ethnic differences may reflect either cultural 
differences, such as the siesta in the Mediterranean countries, or socioeconomic or 
genetic differences. Generally, African Americans tend to sleep more than whites or 
Hispanics (Hanlon and Van Cauter, 2011). Finally, exercise is known to have a 
positive effect on sleep duration and sleep quality by increasing sleep duration, 
decreasing sleep latency, decreasing REM sleep, increasing REM onset latency and 
increasing N2 and SWS (Youngstedt et al., 1997).  
From a study collected in Finland in the year 2000, it was estimated that 28% of 
the population have either shorter (14.5%) or longer (13.5%) sleep duration than the 
average 7–8 hours per day. It is thought that many individuals with short sleep 
Sleep and watchfulness 
both of them, 
when immoderate 
constitute disease. 
Hippocrates 
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duration suffer from sleep debt rather than being natural short sleepers. It is 
estimated that 18–25% of Finnish individuals live in constant sleep debt. (Kronholm 
et al., 2006).  
2.2.10 Sleep Duration and Morbidity 
Sleep duration deviating from the normal 7–8 hours a day has been related to 
mortality (Cappuccio et al., 2010b) and especially to morbidity and mortality from 
metabolic and cardiovascular diseases (Johansson et al., 2011, Kronholm et al., 
2011). During the past three decades the mean sleep duration has decreased in 
Finland while complaints of sleep problems have increased (Kronholm et al., 2008). 
Similar findings have been seen in the United States (Knutson et al., 2010, Rowshan 
Ravan et al., 2010) and Sweden. A study in the United States found a decrease in 
sleep duration that was independent of ethnical background (Hanlon and Van 
Cauter, 2011). Especially large changes have been seen among adolescents (Spruyt 
et al., 2011, Van Cauter and Knutson, 2008). It is estimated that part of the 
population is living in constant sleep debt. At the same time as sleep duration has 
decreased, the percentage of individuals having cardiometabolic diseases has 
increased (Van Cauter and Knutson, 2008, McGuire, 2011).  
Epidemiological studies on sleep duration, sleep quality and insomnia have 
shown that poor sleep and deviating sleep duration are independent risk factors for 
the development of cardiovascular and metabolic diseases such as T2DM, 
hypertension, coronary heart disease (CHD) and obesity. Prospective studies have 
shown that individuals with deviating sleep duration have a higher risk of obesity 
(Knutson, 2010, Patel et al., 2006). Obesity and overweight are also becoming more 
and more common among children and adolescents. In the United States, a quarter 
of the children under five years of age are either obese or have a higher risk of 
becoming obese (McGuire, 2011). Short sleep duration is an independent risk factor 
among both children and adults for obesity and overweight (Buxton and Marcelli, 
2010, Spruyt et al., 2011). Among children especially the variability of sleep 
duration or circadian rhythm between weekdays and weekends predisposes to 
obesity and to higher levels of circulating LDL-C and CRP (Buxton and Marcelli, 
2010).  
Similar findings have been obtained from cardiovascular risk factors in the 
Finnish population. A prospective study performed in Finland discovered that 
deviating sleep duration is an independent risk factor for cardiovascular mortality in 
women even when adjusting for age, smoking, BMI, hypertension or cholesterol 
levels (Kronholm et al. 2011). A similar study in United States found also a 
connection between cardiovascular diseases and deviating sleep duration (Knutson, 
2010). 
Several epidemiological studies have shown that deviating sleep duration 
associates with poor glucose tolerance, T2DM and increased insulin resistance after 
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adjusting for age, gender, BMI, ethnicity and waist circumference. In addition, 
prospective studies have shown that poor sleep quality and deviating sleep duration 
are risk factors for developing T2DM (Cappuccio et al., 2010a, Gottlieb et al., 
2005). Together these epidemiological studies show that sleep duration and sleep 
quality are strongly connected with metabolic regulation. However, the mechanisms 
connecting sleep duration and metabolism are so far only partially understood.  
2.2.11 Experimental Sleep Deprivation  
Sleep deprivation studies have elucidated the connection and mechanisms between 
sleep duration and cardiometabolic diseases. These studies have consistently found 
that glucose metabolism changes after sleep deprivation. The overall levels of blood 
glucose are decreased after sleep deprivation and there is reduced glucose tolerance, 
or increased insulin resistance both in total sleep deprivation studies and in partial 
sleep deprivation studies (Spiegel et al., 1999, van Leeuwen et al., 2010). In 
addition, postprandial glucose and insulin levels are increased in sleep deprivation 
compared to baseline levels (Wehrens et al., 2010).  
Sleep deprived individuals report hunger (Spiegel et al., 2004b, van Leeuwen et 
al., 2010) and increase in activity of the brain reward system for food (St-Onge et 
al., 2012). These observations are partially explained by changes in the levels of 
leptin and ghrelin hormones that modulate satiety and appetite, respectively. Sleep 
deprivation has been shown to increase the levels of the appetite promoting hormone 
ghrelin. Some studies have found a decrease in the levels of the satiety promoting 
hormone leptin, whereas others have found an increase (Spiegel et al., 2004b, van 
Leeuwen et al., 2010). The decrease may reflect acute changes in the levels of leptin 
whereas an increase in leptin levels suggests the development of leptin resistance 
that is also often seen in individuals with high BMI. Some of the changes in leptin 
and ghrelin levels may also be explained by the increased energy expenditure seen 
in sleep deprivation (Caron and Stephenson, 2010). Sleep deprivation also increases 
levels of stress hormones such as serum cortisol (Spiegel et al., 1999) and 
norepinephrine (Dettoni et al.), suggesting an activation of the sympathetic nervous 
system. In contrast, others have reported a dampening of the circadian cortisol 
rhythm after a one-week sleep restriction (Vgontzas et al., 2004). Accordingly, sleep 
deprivation has been shown to increase heart rate and blood pressure (van Leeuwen 
et al., 2010) as well as decrease heart rate variability (Dettoni et al., 2012). However, 
sleep deprivation also increases venous endothelial dysfunction measured by 
endothelial dependent venodilatation (Dettoni et al., 2012). 
The effect of sleep deprivation on lipid metabolism has not yet been fully 
characterized. One study has reported increased total cholesterol and LDL-C after 
sleep restriction in post-menopausal women (Kerkhofs et al., 2007). In contrast, a 
study in rats found evidence for lower total cholesterol levels (TC) after sleep 
restriction (Everson and Szabo, 2011). 
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Several studies have found an increase in CRP levels after sleep deprivation. An 
increase in CRP levels is a marker of inflammation and it has been suggested that 
changes in low-grade inflammation may explain some of the comorbidities of 
deviating sleep duration (van Leeuwen et al., 2009). Accordingly, the number of 
circulating blood leucocytes increases after sleep deprivation. The same study also 
found an increase specifically in monocytes and neutrophils and a trend in decreased 
lymphocyte levels after three nights of partial sleep deprivation (Kerkhofs et al., 
2007). Another partial sleep deprivation study found that B lymphocytes are 
increased and Natural Killer cells (NK-cells) are decreased whereas the total amount 
of T cells is not changed. The same study has also elucidated leukocyte activation 
after sleep deprivation so that after stimulation they are more prone to secrete the 
inflammatory cytokines TNFa, IL-1b, IL6 and IL17 (van Leeuwen et al., 2009). 
Similarly, acute sleep deprivation increases the proinflammatory markers IL1b, IL6 
and TNFa (Irwin et al., 2006), suggesting a possible mechanism for inflammatory 
activation after sleep deprivation.  
Finally, sleep deprivation has a strong effect on mental health and performance. 
Sleep deprivation increases reaction time and daytime sleepiness, and decreases 
cognitive performance and mood (Van Dongen et al., 2003, Van Dongen and 
Dinges, 2003, Dinges et al., 1997).  
The recovery of sleep deprivation depends on the magnitude of the restriction 
(homeostasis). The changes observed after one night of total sleep deprivation 
usually recover during the first recovery night whereas partial sleep deprivation 
studies need at least two nights of recovery. For example, heart rate did not recover 
after two nights of recovery (van Leeuwen et al., 2010) but was even increased after 
the recovery period even though changes in glucose metabolism recovered (van 
Leeuwen et al., 2009, van Leeuwen et al., 2010).  
A few studies have also investigated the role of sleep extension on physiology. 
Unlike in the epidemiological studies, so far these studies have not found harmful 
effects of prolonged sleep on physiology, suggesting that the mechanism between 
longer sleep duration is either comorbid with other diseases after disease onset or 
that longer exposure to long sleep duration is needed in order to see the 
disadvantageous effects (Spiegel et al., 2004a).  
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2.2.12 Genetics of Sleep and Sleep Disorders 
Sleep duration is a complex genetic trait. The heritability estimates of normal self-
reported sleep duration range from 31% to 44% (Partinen et al., 1983, Heath et al., 
1990, Watson et al., 2010). Heritability estimates for sleep traits are presented in 
Table 1. The first GWA study on sleep and circadian traits, performed in 2007 
(Gottlieb et al., 2007), identified one genome-wide significant SNP in PDE4D with 
sleepiness. However, only one common genetic variant contributing to normal sleep 
duration has been characterized. This variant is located in the ABCC9 gene that 
encodes for the K(ATP) channel (Allebrandt et al., 2011).  
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Table 1. Heritability estimates for sleep and mood. Heritability is defined by the 
genetic variation in proportion to phenotypic variation. Heritability, 
estimated from twin and family studies, show substantial heritability for 
sleep phenotypes and traits that have been associated with sleep duration: 
Electroencephalography (EEG), bipolar disorder (BD), total cholesterol 
(TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), body mass index (BMI). 
Trait Heritability Study description Reference 
Sleep length 0.33-0.45 2238MZ, 4545 DZ Partinen et al., 1983 
EEG 0.96 20MZ, 20DZ De Gennaro et al., 2008 
EEG delta 0.76 91MZ, 122DZ Van Beijsterveldt et al., 1996 
EEG theta 0.89 91MZ, 122DZ Van Beijsterveldt et al., 1996 
EEG alpha 0.89 91MZ, 122DZ Van Beijsterveldt et al., 1996 
EEG beta 0.86 91MZ, 122DZ Van Beijsterveldt et al., 1996 
Chronotype 0.5 2863 MZ, 5917 DZ Koskenvuo et al., 2007 
Epworth 
sleepiness 
scale 
0.38 818MZ, 742 DZ Carmelli D et al., 2001 
Sleep 
quality 0.44 2238MZ, 4545 DZ Partinen et al., 1983 
Insomnia 0.28-0.48 1605MZ, 1200DZ 1554 MZ, 2991 DZ 
McCarren et al., 1994,  
Hublin et al., 2011 
Depression women 0.42 men 0.29 Swedish twin sample N= 42161 Kendler et al., 2006 
BD 0.73-0.93 
Finnish BD family N=723  
30 MZ and 37 DZ British twins, 
Norwegian same sex twins 
N=303 
Edvarsen et al., 2008,  
Kieseppa et al., 2004,  
McGuffin et al. 2003, 
TC 0.58-0.71 100 MZ, 72DZ, 52 MZ, 89DZ Knoblauc et al.,  1997, Pietilainen et al., 2009 
HDL-C 0.61-0.73 100 MZ, 72DZ, 52 MZ, 89DZ Knoblauc et al.,  1997, Pietilainen et al., 2009 
LDL-C 0.59-0.79 100 MZ, 72DZ, 52 MZ, 89DZ Knoblauc et al.,  1997, Pietilainen et al., 2009 
TG 0.66-0.3-0.4 100 MZ, 72DZ 52 MZ, 89DZ Knoblauc et al.,  1997, Pietilainen et al., 2009 
BMI 0.73 Meta-analysis N=140 525 twins Knoblauc et al., 1997,  Elks et al.,2012 
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2.2.12.1 Genetic Findings in Sleep Disorders 
The most common sleep-wake disorders are insomnia and sleep apnea. Chronic 
insomnia is defined by difficulties in sleep onset or in sleep maintenance, early 
awakenings and not feeling refreshed after waking up. The prevalence of insomnia 
ranges from 9% to 24% and it is more common in women than in men. Insomnia 
symptoms increase with age and it is related to higher mortality (Buscemi et al., 
2005, Daley et al., 2009) as well as to other comorbidities such as depression, 
cardiovascular diseases, anxiety and dementia (Hale, 2005). Insomnia may be a 
result of over activation of the wake-promoting systems. So far, no genome-wide 
significant findings have been found with insomnia. One GWAS has been published 
and the most significant findings were located in the receptor tyrosine kinase-like 
orphan receptor 1 (ROR1) and phospholipase C, beta 1 (PLCB1) (Ban et al., 2011). 
However, these findings did not reach genome-wide significance. The genome-wide 
significant findings with sleep and sleep disorders are presented in Table 2. 
Table 2. Genetic findings with sleep and sleep disorders from GWA and sequencing 
studies. 
 
Trait Gene Leading variant Reference 
Sleep duration ABCC9 rs11046205 Allebrandt et al., 2011 
Sleepiness PDE4D rs1823068 Gottlieb et al., 2007 
Narcolepsy HLA HLA-DQ(B1/A1) Matsuki et al., 1992 
Narcolepsy TCRa rs1154155 Hallmayer et al., 2009 
Narcolepsy CPT1B, CHKB rs5770917 Miyagawa et al., 2008 
Narcolepsy P2RY11 rs2305795 Kornum et al., 2011 
Familial short sleep DEC2 P385R He et al., 2009 
Narcolepsy DNMT1 V606F/A570V/G605A Winkelmann  et al., 2012 
Restless legs syndrome MEIS1 rs6747972 Winkelmann et al., 2007 
Restless legs syndrome BTBD9 rs9296249 Winkelmann et al., 2007 
Restless legs syndrome MAP2K5-LBXCOR1 rs1026732 Winkelmann et al., 2007 
Restless legs syndrome PTPRD rs4626664 Schormair et al., 2008 
Restless legs syndrome TOX3 rs3104767 Winkelmann et al., 2011 
Restless legs syndrome NOS1 rs7977109 Winkelmann et al., 2008 
 
Sleep apnea is characterized by discontinuous and reduced breathing during 
sleep. The severity of the apnea is based on the number of apnea (total loss of 
airflow) and hypopnea (partial loss of airflow) events per hour, or the apnea-
hypopnea index. Sleep apnea is relatively common with prevalence estimates 
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ranging up to 28% with mild sleep apnea, and up to 14% with moderate sleep apnea. 
Sleep apnea is more common and more severe in men than in women and it is 
related to cardiovascular risk factors, T2DM, hypertension and poor quality of life 
(Young et al., 2002). No genome-wide significant findings have been published on 
sleep apnea.  
The most common sleep related movement disorder is restless legs syndrome 
(RLS). It is characterized by the need to move the feet or arms during sleep. 
Individuals with RLS also often suffer from interrupted sleep or difficulties in 
falling asleep. RLS affects 10.6% of the population (Winkelman et al., 2006) even 
though larger prevalence estimates up to 24% have been reported (Garcia-
Borreguero et al., 2006). The prevalence of RLS increases with age and it is related 
to other comorbidities like increased daytime sleepiness, depression, anxiety and 
cardiovascular diseases (Winkelman et al., 2006). The causes of RLS are not fully 
understood but iron metabolism is related to RLS, as secondary RLS can be caused 
by iron deficiency (Allen and Earley, 2007). Patients with RLS benefit from 
dopamine agonists while individuals with Parkinson’s disease often suffer from 
RLS, suggesting that dopamine signaling may have a role in RLS (Montplaisir et al., 
1986).  
Unlike in most other sleep disorders, a few specific loci contributing to the 
genetic aetiology of RLS have been characterized. These genome-wide significant 
findings are located in BTBD9, MEIS1, PTPRD, and three intergenic regions 
between MAP2K5 and SKOR1, TOX3 and non-coding RNA BC034767, and in 
chromosome 2p14. The potential target genes included MEIS1 as well as ETAA1 in 
this region (Schormair et al., 2008, Winkelmann et al., 2011, Winkelmann et al., 
2008, Winkelmann et al., 2007). Functional studies on BTBD9 and MEIS1 knockout 
animals have supported their role in the etiology of RLS. BTBD9 deficient animals 
show sleep and motor function disturbances as well as elevated iron levels in serum 
(Deandrade et al., 2012). Similarly, MEIS1 deficient c. elegans show increased 
ferritin levels (Catoire et al., 2011). 
Hypersomnias are characterized by increased daytime sleepiness, difficulties in 
maintaining wakefulness or increased sleep need. The most common hypersomnias 
include narcolepsy and idiopathic hypersomnia. Narcolepsy is characterized by 
increased sleep duration, episodes of cataplexy (loss of muscle tone) that is often 
triggered by positive emotions. The human leukocyte antigen (HLA) allele HLA 
DQB1*0602 has been strongly associated with narcolepsy (Mignot et al., 2001). 
Individuals with narcolepsy have low levels or absent hypocretin (orexin) in the 
cerebrospinal fluid (Nishino et al., 2000). It is thought that narcolepsy is an 
autoimmune disease that is caused by the destruction of hypocretin neurons in the 
hypothalamus. GWAS findings have supported this hypothesis, as most of the 
variants with narcolepsy are located in immunological genes (Hallmayer et al., 2009, 
Kornum et al., 2011). 
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2.2.12.2 Genetic Findings in Circadian Pace Maker Genes and Melatonin 
Receptors in Metabolic Diseases 
The connection between sleep disorders or sleep with cardiovascular and other 
metabolic diseases seems to be bidirectional also at the genetic level. Genome-wide 
association studies on blood glucose levels and T2DM have found common variants 
in clock genes, such as CRY2 and in melatonin receptor gene MTNR1B (Ingelsson et 
al., 2010) and more recently also rare variants in MTNR1B (Bonnefond et al.). 
Candidate gene studies of clock genes on metabolic traits have found associations 
with BMAL1, PER2 and NPAS2 with T2DM and hypertension (Englund et al., 2009, 
Monteleone et al., 2008, Woon et al., 2007).  
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2.3 Sleep in Psychiatric Diseases 
Sleep disturbances are frequent in 
psychiatric diseases. The 
connection between sleep and 
psychiatric diseases is clearly 
bidirectional. Sleep disturbances 
predispose to psychiatric diseases 
and psychiatric diseases change 
sleep architecture or cause sleep 
disturbances (Borbely et al., 1984, 
Paunio et al., 2009). The connection 
of sleep with psychiatric diseases is 
best characterized by depression. 
Ninety percent of individuals 
suffering from depression have sleep difficulties (Kupfer, 1984). The most common 
sleep problems are insomnia and hypersomnia. Sleep problems are thus common in 
major depression. In addition, 40% of individuals who are diagnosed with insomnia 
have a psychiatric disorder and 46.4% of individuals with hypersomnia have 
psychiatric disorders (Ford and Kamerow, 1989). The relationship between sleep 
and depression is thus bidirectional as individuals with major depressive disorder 
report sleep problems and individuals with sleep problems report negative mood or 
depression (Ryan et al., 1987). These findings suggest that sleep disturbances and 
depression are (1) either comorbid or that (2) one is a risk factor for the other. 
Longitudinal studies have supported the latter. A study performed in twins in 
Finland found that poor sleep was an independent risk factor for developing life 
dissatisfaction after a six-year follow-up (Paunio et al., 2009). Other prospective 
studies have found similar effects with insomnia on depression and other psychiatric 
disorders (Breslau et al., 1996, Weissman et al., 1997). These studies suggest that 
sleep problems may be the first signs of a developing depression. On the other hand, 
sleep problems may be independent risk factors. 
In depression and in other psychiatric diseases the characteristics of EEG change. 
Patients suffering from depression have increased amounts of REM sleep, shorter 
REM sleep latency, decreased amounts of SWS and increased amounts of light 
NREM sleep N1 and more fragmented sleep (Borbely et al., 1984). Quite strikingly, 
individuals suffering from depression have a short-time benefit from total sleep 
deprivation that is reversed with recovery sleep (Wu and Bunney, 1990). This effect 
seems to be mediated through REM sleep deprivation as REM sleep deprivation 
alone, but not NREM sleep deprivation, can elevate mood (Vogel et al., 1980). 
Individuals with depression are also more prone to suffer from jet lag or shift work, 
suggesting that the circadian system affects the etiology of depression. For example, 
Nightmare by Henry Fuseli (1741–1825)
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circadian misalignment and shift work worsen depressive symptoms (Cole et al., 
1990, Emens et al., 2009, Scott et al., 1997) 
Besides major depressive disorder, seasonal affective disorder (SAD), 
schizophrenia, anxiety disorders and bipolar disease (BD) are closely related to 
disturbances in sleep-wake regulation (Hakkarainen et al., 2003, Jones et al., 2005). 
The early symptoms of BD include sleep problems that are seen both in bipolar 
depression and at the onset of mania (Jackson et al., 2003). In BD the role of the 
circadian rhythm has come up repeatedly. BD patients also have shorter sleep need, 
larger seasonal variation in mood and a less stable, more variable circadian rhythm 
(Hakkarainen et al., 2003, Jones et al., 2005). The physiological and genetic 
mechanisms linking sleep disturbances with psychiatric diseases are largely 
unknown. Two theories suggest that stress may play a role in this connection. The 
first theory suggests that low levels of BDNF could cause depression. It has been 
shown that stress reduces BDNF levels in the brain and antidepressant treatment 
increases the amount of BDNF (Duman and Monteggia, 2006). Another stress-
induced pathway suggests the involvement of the hypothalamic-pituitary-adrenal 
(HPA) axis, which is known to act in stress (Hafez and Hafez, 2004). Accordingly, 
individuals that suffer from depression have higher plasma cortisol levels (Burke et 
al., 2005) and higher corticotropin-releasing hormone mRNA levels (Merali et al., 
2004), suggesting higher activity of the HPA axis.  
As sleep disturbances are seen with all psychiatric diseases, it is likely that there 
are some common factors contributing to mood disorders and sleep regulation. 
Recently, this connection has been studied at the genetic level with depression. Two 
candidate gene studies (Utge et al., 2011, Utge et al., 2010) evaluated the shared 
genetic background for sleep and depression with sleep disturbance. These studies 
found evidence for specific genetic variants in glutamatergic (GRIA3, GAD1, P2RX7 
and DAOA), serotonergic (SLC6A4 and TPH2), neural plasticity (DISC1, CREB1 
and BDNF), and HPA axis genes (CRHR1) (Utge et al., 2011) that associated with 
distinct subtypes of depression with either early morning awakenings or fatigue. 
These earlier findings suggest that the variants also regulate aspects of sleep in 
depression. One of these detected variants in GRIA3 was also found to contribute to 
normal sleep regulation in healthy individuals (Utge et al., 2011), suggesting a 
shared genetic regulation but also evidencing that these variants may be important in 
normal sleep duration.  
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3 Aims of the Study 
Both epidemiological and experimental studies have indicated a connection between 
sleep duration and various detrimental health conditions, including metabolic 
diseases and mood disturbances, but the links between sleep and these conditions 
have remained largely unexplored.  
The main aim of the present study was to elucidate genetic factors and variants 
that contribute to regulation of human sleep duration and timing, and to elucidate 
their connections to metabolism and mood disorders.  
 
Specifically the aims of this thesis were to 
 
1. Characterize genes and genetic variants that contribute to normal 
 sleep duration (I). 
 
2. Elucidate the cellular mechanisms of short sleep and the effect of 
sleep deprivation on physiology (I and unpublished). 
 
3. Elucidate the connection of sleep with somatic (II) and 
 psychiatric (III, IV) diseases at the genetic level. 
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4 Materials and Methods 
4.1 Study Subjects 
Figure 8 illustrates the study design for each study. The number of individuals for 
the cohorts is presented in Table 3. The selection criteria for the individual cohorts 
and the sub cohorts are described below.  
 
Discovery 
samples
I
GWAS of sleep duration
II
Common variants in 
sleep and metabolism
III
Depression and variants 
in adenosine metabolism
IV
Bipolar disorder variants
in sleep and cognition
Genmets 
Health 2000 sub cohort
N= 1941
Health 2000, N=5948 in 
genetic and 
epidemiological analysis
Finrisk07  N=635 in 
genetic analysis, 
N= 6092 in 
epidemiological analysis 
Cases: Depression, N=383 
from Health 2000
Controls: Healthy sleepers 
from Health 2000, N=1357
Bipolar family sample 
N=723, 258 affected
Circadian phenotypes
N=127, 37 families
Follow-up
samples
Health 2000, N= 3389
YF, N=2028
DILGOM, N=518
Finnish Twins, N=765
Functional
studies
Bipolar signals from
Sklar et al., 2008
WTCCC et al., 2007
Finnish Twins, N=2189
Health 2000 early 
morning awakenings
N= 316 cases, 691 
controls  (unpublished)
RNA expression in 
DILGOM, N=518
RNA epxression after 
sleep restriction 
N=13 (9 cases)
RNA epxression after 
sleep restriction 
N=13 (9 cases)
 
Figure 8. Study design. Discovery and follow-up samples are presented. Study I and III 
include independent discovery and follow-up samples. For study II the markers 
were selected based on a GWA study of lipid traits published by Teslovich et al., 
2010 and studied for sleep duration in the Finnish population-based sample Health 
2000 and Finrisk07. For study IV the variants were selected based on published 
association studies on bipolar disorder (Baum et all., 2008a, Ollila et al 2009 and 
WTCCC 2007) and it consists of a follow-up of those variants in the Finnish 
bipolar family sample. 
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Table 3. The number of individuals in each cohort and study.  
Subjects N Study Description 
Health 2000 
6,269 II 
Epidemiological sample for studying blood lipid 
levels and sleep duration. Discovery sample for 
association analysis of known lipid SNPs with 
sleep duration 
GenMets1,941 I Discovery for sleep duration. 
Healthy SleepersA1,357 
II, 
III 
Association analysis of sleep duration and known 
lipid SNPs was studied in healthy individuals (II), 
control sample for depression (III) 
DepressionA383 III Cases sample, depression with disturbed sleep (III) 
Finrisk07 
7,993 II 
Epidemiological sample for studying blood lipid 
levels and sleep duration.  Follow-up sample for 
association analysis of sleep duration (I) and 
discovery sample for association analysis of sleep 
duration and known lipid SNPs (II).  (N=652 for 
genetic variants I, II). 
DILGOM RNA 
expression
518 I 
Follow up sample for GWAS variants from 
GenMets (I). 
YF 
2,028 I 
Follow up sample for GWAS variants from 
GenMets (I). 
Older Finnish Twin 
cohort 
2,189 I, II 
Replication sample for II. Follow up sample for 
GWAS variants from GenMets (I). 
Finnish Bipolar Family 
Sample 723 (258 
affected) 
IV 
Replication sample for GWA-studies in Bipolar 
disorder. Sample for studying intermediate 
phenotypes (endophenotypes) for bipolar disorder. 
Experimental Sleep 
Restriction 13 (9 cases) I, II 
Follow up sample for I and II. RNA expression 
analysis and correlation analysis of variants with 
EEG slow wave sleep. 
A The depression group was divided into sub groups based on fatique (N=194 
women, 103 men) or early morning awakenings (N=109 women, 103 men). Overlap 
in groups “depression with early morning awakenings” and “depression with fatigue” 
was 95 for women and 58 for men. The Healthy sleepers and Depression sub groups 
did not overlap as Healthy sleepers were used as controls for the Depression group. 
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4.1.1 Health 2000  
The Health 2000 study (http://www.terveys2000.fi/doc/methodologyrep.pdf) is 
Finnish nationwide survey collected in 2000–2001. The study subjects of the study 
were selected from the Social Insurance Institution (SII) of Finland (Kela) based on 
the criteria that they would reflect the main demographic distributions of the Finnish 
population. The main aims of the survey were to characterize the public health 
problems in Finland, including areas on physical and mental health and work-related 
traits. The study consisted of home interview and a health examination including 
laboratory examination conducted at a local health center. Blood samples for DNA 
extraction were taken. Altogether Health 2000 comprised of 8,028 individuals (54% 
females) over 30 years of age of which 6,269 returned the sleep duration 
questionnaire. The data collection was conducted earlier by the National Institute for 
Health and Welfare. Selection of sub groups was done for each study separately (I-
III). 
Studies I and II include 6,269 study subjects belonging to Health 2000 who 
answered the sleep duration and who had DNA available for analyses. In addition, 
1,894 individuals aged 18-29 belonged to Health 2000 sample of Young Adults sub 
study. They did not answer the questions about sleep and are thus not included in the 
analyses discussed in this thesis. A written informed consent was obtained from 
participants. The study was approved by the ethics committee of the Helsinki 
University Central Hospital. 
4.1.2 Health 2000 sub cohorts: GenMets, Healthy sleepers and 
Depression 
GenMets 
As the discovery sample for genome-wide association analysis of sleep duration (I) 
we used previously collected GenMets subcohort (N=1,941) belonging to Health 
2000. Originally the GenMets sample was collected in order to study metabolic 
syndrome: half of the individuals belonging to the GenMets study had metabolic 
syndrome and half of them were age and gender matched controls (Kristiansson et 
al., 2012). For the metabolic syndrome study also genome-wide chips were done in 
the GenMets sample (see section 4.3). 
Metabolic syndrome was defined according to the International Diabetes Federation 
(IDF) criteria (http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf) in 
GenMets, i.e., waist circumference ≥ 94cm in males and ≥80cm in females. In 
addition, the subjects had to have two of the following four criteria: 1) blood 
triacylglycerols ≥ 1.7mmol/l, blood HDL-C in males ≥1.03mmol/l and in females 
≥1.29mmol/l, 2) systolic blood pressure ≥ 130mm/Hg or diastolic blood pressure 
≥85mm/Hg or 3) medication for treating blood pressure and 4) glucose levels ≥ 
5.6mmol/l.  
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During the Health 2000 data collection the individuals also answered to the question 
about sleep duration. We thus utilized the ready genotypes and questionnaire based 
information of the sleep duration for study I. The study was approved by the ethics 
committee of Helsinki University Central Hospital. Additional genotyping was 
performed to cover the whole Health 2000 study for the variants that showed point 
wise association P<5*10-5 in GenMets. 
 
Healthy Sleepers 
The individuals in the Health 2000 cohort that did not have depression or other sleep 
complaints (N=610 women and N=525 men) were defined as Healthy sleepers (II, 
III). These individuals were originally selected in order to get healthy controls for 
depression cases (III, Utge et al., 2010). For study II these individuals were studied 
in order to characterize the association of lipid gene SNPs with normal sleep 
duration without confounding sleep problems. These individuals also served as 
healthy controls in the depression study III. For these individuals and markers we 
performed genotyping but phenotypes collected during Health 2000 collection were 
used. 
 
Depression 
Individuals with major depressive disorder were selected from the population-based 
Health 2000 cohort for study III and previously published work (III, Utge et al., 
2010). The sample comprised 1,423 unrelated individuals (N cases = 258 women, 
125 men and Healthy sleepers were used as controls, N controls = 557 women 483 
men) with an age range of 30–88 years from 80 regions of Finland. Depression, i.e. 
major depressive disorder, during past 12 months, was diagnosed according to the 
Diagnostic and Statistical Manual (DSM-IV) definitions and criteria for psychiatric 
disorders by using the research version of the Composite International Diagnostic 
Interview (CIDI) (Pirkola et al., 2005). The controls did not have depression (III). 
The depression group was divided into sub groups based on phenotypes: fatigue 
(N=194 women, 103 men) or early morning awakenings (N=109 women, 103 men). 
Overlap in groups “depression with early morning awakenings” and “depression 
with fatigue” was 95 for women and 58 for men. The Healthy sleepers and 
Depression sub groups did not overlap as Healthy sleepers were used as controls for 
Depression group. For these individuals and markers we performed genotyping but 
phenotypes collected during Health 2000 collection were used. 
4.1.3 Finrisk  
The Finrisk studies aim to characterize cardiovascular risk factors in the Finnish 
population. These studies were done by the National Institute for Health and 
Welfare. The first study was conducted on 1972, after which cross-sectional studies 
have been performed every five years (http://www.ktl.fi/finriski). The Finrisk07 
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study discussed in this thesis included 7,993 individuals (53% females) from six 
areas of Finland: Helsinki and Vantaa, Turku and Loimaa, and the provinces of 
North Savo, North Karelia, Oulu and Lapland. The study consisted of home 
interview and a health examination including laboratory examination.  
 
DILGOM Sub-study 
The Dietary Lifestyle and Genetic determinants of Obesity and Metabolic Syndrome 
(DILGOM) study was originally performed as an extension of the Finrisk 2007 
study (Inouye et al., 2010). The aim of the whole DILGOM study was to 
characterize risk factors for metabolic and cardiovascular diseases in the Finnish 
population both in epidemiological and in genetic level. The individuals were 25-74 
years of age and information on their general and mental health was collected. 
Altogether, 518 individuals (54% females) had both genotypic and phenotypic 
information on their sleep duration and genome-wide RNA expression. These 
individuals were included in the follow-up data set for study I in order to study the 
variants associating with sleep duration in a larger sample of Finnish individuals. 
DILGOM was also a part of the discovery sample for study II together with the 
whole Health 2000 sample. A written informed consent was obtained from 
participants. The study was approved by the ethics committee of the Helsinki 
University Central Hospital.  
In the DILGOM RNA expression sample (I), the RNA expression was measured 
from 518 individuals belonging to the DILGOM data set (Inouye et al., 2010). For 
RNA expression analysis the biotinylated cRNA from 518 individuals from the 
DILGOM cohort were hybridized onto Illumina HumanHT-12 Expression 
BeadChips (Illumina Inc., San Diego, CA, USA), using standard protocol. For each 
sample, biotinylated cRNA preparation and hybridization onto BeadChip were done 
in duplicates (Inouye et al., 2010). In this sample previously made genome-wide 
chips and previously assessed phenotypes were used in studies I and II. 
4.1.4 Older Finnish Twin Cohort  
The Older Finnish Twin Cohort was started in 1975 and follow ups were done in 
1981 and 1990 (Kaprio and Koskenvuo, 2002). Sleep duration was assessed in all 
years by questionnaires and the answers from 1981 were used in the analysis. 
Altogether 2265 individuals from 762 families participated in the study of which 
765 individuals were used in the study I follow-up sample (Kaprio and Koskenvuo, 
2002). The study was approved by the ethics committee of the Helsinki University 
Central Hospital. The twin cohort was used as a follow-up cohort in studies I and II. 
For study I previously made genotypes were used whereas for study II we genotyped 
the follow-up markers. 
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4.1.5 Young Finns  
The Cardiovascular Risk in Young Finns Study (YF) is a prospective cohort. It aims 
to study cardiovascular risk factors in children and adolescents (aged 3, 6, 9 and 18). 
The study participants were selected randomly (Jylhava et al., 2012). The first 
collection was conducted in 1980. Sleep duration was assessed on 2007 when the 
study subjects were 30 to 45 years of age. A written informed consent was obtained 
from participants and the study was approved by the ethics committee of University 
Hospital of Turku (Jylhava et al., 2012). For the study I we used previously done 
genome-wide genotypes and questionnaire-based sleep duration phenotype. 
Altogether 2028 individuals had both genotype and phenotype information. 
4.1.6 Finnish Bipolar Family Sample 
The Finnish bipolar family sample (Ekholm, et al., 2002) is comprised of altogether 
723 individuals from 180 families of Finnish origin (IV). In the study IV we 
analyzed the association of suggestive genome-wide significant findings from two 
earlier publications for BD (Sklar et al., 2008, WTCCC 2007). In the Finnish bipolar 
family sample we used bipolar disease and any mood disorder as phenotypes. The 
affected individuals in this data set (N=258) had a variety of psychiatric symptoms: 
bipolar spectrum disorder (N=173), psychotic disorder (N=212) and other mental 
disorders (N=45).  
In addition, we followed-up the SNPs that associated with BD in the Finnish 
bipolar family sample and studied their association with endophenotypes. The 
endophenotypes included circadian and global seasonality phenotypes that were 
assessed with morningness eveningness questionnaire and seasonality questionnaire 
(Horne and Ostberg, 1976, Rosenthal, 1984). These phenotypes were characterized 
from a subset of 127 individuals from 37 families, and neuropsychological 
phenotypes were characterized from 159 individuals in 65 families. The 
neuropsycghiological tests included 22 neuropsychological test variables from the 
Wechsler Adult Intelligence Scale Revised (WAIS-R), the Wechsler Memory Scale 
Revised (WMS-R), the California Verbal Learning Test, the Stroop Color and Word 
Test and the Controlled Oral Word Association Test. The study was approved by the 
Ministry of Social Affairs and Health and the Ethical Committee of the National 
Public Health Institute. In the Finnish bipolar family sample the markers were 
genotyped for study IV. 
4.1.7  Experimental Sleep Restriction Study 
The sleep restriction study was originally collected in collaboration with the Finnish 
Institute of Occupational Health to study the effects of insufficient sleep on human 
physiology (van Leeuwen et al., 2010, van Leeuwen et al., 2009). In short, thirteen 
healthy men with complete data, aged 19–29 with a mean age of 23.1±2.5 years 
participated in the study. All had a regular sleep-wake schedule and habitual sleep 
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duration of 7–9 h. The experiment group (N = 9) spent 8 h in bed for the first two 
baseline nights, from 11 PM to 7 AM, followed by 5 nights of sleep restriction, 
where they spent only 4 h in bed from 3 AM to 7 AM.  Two recovery nights of 8 h 
in bed 11 PM to 7 AM ended the experiment. The control group (N = 4) spent 8 h in 
bed (11 PM to 7 AM) throughout the experiment. EEG recordings (Embla, Flaga 
HF, Reykjavik, Iceland), using a sampling rate of 200 Hz with a bandwidth of 0.5–
90 Hz and a continuously present investigator monitored that the participants did not 
sleep or nap during the periods outside those mentioned above. Energy intake was 
controlled by meals that were standardized and energy-balanced based on the current 
national recommendations and they were provided at fixed times of the day and 
consumed by all participants throughout the experiment. The study design was 
approved by the ethics committee of the Helsinki University Central Hospital and a 
written informed consent was obtained from the participants. The experiment was 
conducted at the Brain and Work Research Centre of the Finnish Institute of 
Occupational Health (van Leeuwen et al., 2009).  
In the sleep deprivation study used in study I and II, RNA was collected from 
blood mononuclear leucocytes in the morning after baseline, restriction and in 
recovery phases using a Qiagen RNA easy extraction kit (QIAGEN, Hilden, 
Germany). The RNA expression levels were tested using Affymetrix U133 Plus 2.0 
human genome expression arrays (Affymetrix, Santa Clara, CA, USA). We first 
performed quality control (QC) for the transcripts in the genome-wide RNA 
expression chips, Affymetrix GeneChip Human Genome U133 Plus 2.0 that were 
done in the sleep restriction sample. QC of the expression arrays was performed 
with GeneSpring GX software (Agilent Technologies, Palo Alto, CA, USA) and two 
individuals with poor array quality were excluded. The GC RMA algorithm was 
used for normalizing the data. The Affymetrix detection calls were used for filtering 
criterion and probes flagged ‘present’ or ‘marginal’ in more than 2/3 of the samples 
were kept in the analysis. Ensemble database probe set definitions (version 
homo_sapiens_core_54_36, 8.6.2009) were used for annotating the probes to 
respective genes. 15,101 probes remained in the analysis after QC. The outcomes 
used in studies I and II included RNA expression analysis of candidate genes in 
baseline and in sleep restriction. The RNA expression levels were also correlated 
with the amount of slow wave sleep. In addition, pathway analysis of genes reacting 
to sleep restriction was performed to study the overall changes in RNA expression 
after sleep restriction and the effect of sleep restriction on physiology (unpublished 
results). 
4.2 Phenotypes 
Sleep length was evaluated with a similar question in all cohorts: ”How many hours 
do you sleep per day?” and depending on the cohort the individuals could either 
write down a number (Health 2000 and Finrisk 2007) or circle an answer (The older 
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Finnish Twin Cohort and YF). Sleep duration showed normal distribution in all 
studied cohorts. The chronotypes of the individuals using questions 4, 7, 9, 15, 17 
and 19 derived from the morningness-eveningness questionnaire (Horne and 
Ostberg, 1976). In the twin sample, chronotype was assessed by asking “Try to 
estimate, whether you are a morning or evening type person”. The answering 
options were: “clearly morning-type”, “a bit morning-type”, “a bit evening-type”, 
“clearly evening-type”. We hypothesized that different genetic variants would 
contribute to eveningness and morningness. The individuals were thus assigned as 
morning-type, evening-type or neither of the extreme types, and analyzed against the 
group that did not show clear preference toward either chronotype. The Finnish 
version of Epworth sleepiness scale was used to evaluate daytime dozing in the 
Health 2000 study. The questions were: “How easily you fall asleep when 1) sitting 
and reading 2) watching television 3) sitting inactive in a public place 4) as a 
passenger for an hour in a car 5) lying down to rest in the afternoon 6) when talking 
with someone 7) when the car is stopping at traffic lights?”. Fatigue was assessed 
with a question: “Are you more tired during the day than other people of your 
age?”.  
In the Finnish bipolar family sample, circadian and global seasonality 
phenotypes (Horne and Ostberg, 1976, Rosenthal NE, 1984) were characterized 
from a subset of 127 individuals from 37 families, and neuropsychological 
phenotypes were characterized from 159 individuals in 65 families. These tests 
included 22 neuropsychological test variables from the Wechsler Adult Intelligence 
Scale Revised (WAIS-R), the Wechsler Memory Scale Revised (WMS-R), the 
California Verbal Learning Test, the Stroop Color and Word Test and the Controlled 
Oral Word Association Test. 
The metabolic phenotypes from circulating blood included total cholesterol (TC), 
triacylglycerols TG, high-density lipoprotein cholesterol (HDL-C), C-reactive 
protein (CRP), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose 
and fasting plasma insulin. 
In the Finrisk 07 sample, TC was measured with the CHODPAP-assay, HDL-C 
with a direct enzymatic assay and TG with the enzymatic GPO assay (Abbott 
Laboratories, Abbott Park, Illinois, USA). In the Health 2000 sample HDL-C 
(Roche Diagnostics, Mannheim, Germany). TC and TG were measured using 
enzymatic assays (Olympus System Reagent, Hamburg, Germany). 
4.3 Genotyping and Quality Control 
Genotyping was performed with Illumina whole genome chips (Illumina Inc. San 
Diego, CA, USA) in the Welcome Trust Sanger Institute, Cambdridge. Health 2000 
sub study GenMets was genotyped with the Illumina 610 K (Kristiansson et al., 
2012). Individuals from DILGOM were genotyped with the same platform while 
Illumina 670 K platform had been used for the Older Finnish Twin Cohort and YF 
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(Inouye et al., 2010, Kaprio 2002, Jylhava et al., 2012). Individual markers for 
follow-up in study I were selected based on the association in the GenMets sample 
and further studied in DILGOM, YF, Finnish Twins and rest of the individuals 
belonging to Health 2000 study. The Illumina 670 K platform covered all SNPs 
selected for follow up study except for one SNP (rs35496280) which was excluded 
from the analysis. For genotyping accuracy individuals and markers with missing 
data over 5% were removed from the analysis in the GWA. Gender check, 
heterozygosity and relatedness check were performed and individuals with IBD over 
0.2, or discrepancy in gender were removed in all samples with GWA data available. 
Hardy Weinberg P-value threshold was 1*10-6 and markers with AF≥1% were kept 
in the GWA analysis. 
As genome-wide chips were not available from the whole Health 2000 study 
(except for GenMets sub cohort) the variants chosen for follow-up in I were 
genotyped in that sample with Sequenom Mass array technology (Sequenom Inc. 
San Diego, CA, USA), based on single base extension and iPLEX Gold chemistry in 
FIMM Technology Center, Biomedicum, Helsinki. This method was also used 
studies II-IV with the exception of the genotypes for the 635 individuals in study II 
and for the follow-up of SNP rs12256138 in the GenMets sample (III) that were 
obtained from the Illumina 670 and 610 platforms, respectively. 
In the QC for the candidate SNPs individuals and markers with missing data over 
5% were removed from the analysis. Hardy Weinberg P-value threshold was 0.001. 
Markers with AF≥1% were kept in the analysis. 
 
4.4 Statistical Analyses 
4.4.1 Epidemiological Analysis 
We studied the association of sleep duration with blood lipid levels (II). The 
association was tested in Finrisk07 (N=6,092) and in the Health 2000 (5,948) sample 
using the general linear model (GLM). The analyses were performed using PASW 
Statistics 18 and all analyses were adjusted for relevant covariates (age, gender, lipid 
medication, hypnotics, BMI and cohort). 
4.4.2 Association Analysis and Haplotype Analysis 
Sleep duration showed normal distribution in the population level in Health 2000 
and Finrisk07 samples. For the GWA study of sleep duration in GenMets and for 
analyses in the follow-up samples YF, DILGOM, Finnish Twins and rest of the 
Health 2000 cohort (I), the phenotype (sleep duration) was standardized in each 
sample by using the standard-beta option provided by PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell et al., 2007). Linear 
regression analysis was used to perform the association analysis and the analysis 
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was adjusted for age, gender, BMI as well as for genomic principal components 
(GenMets (Kristiansson et al., 2012), DILGOM, YF and the Finnish Twin sample) 
and metabolic disorder status (GenMets sample). Adjusting the genetic association 
analyses by the genomic principal components is a method used to correct for 
population stratification. Fixed effects meta-analysis was performed for calculating 
P-values using PLINK. Analysis for gene environment interaction was performed 
using option gxe provided by PLINK (I, III). 
Haplotype analysis (I) was performed using Haploview (Barrett et al., 2005) and 
phasing was performed using Beagle (Browning and Browning, 2011). This 
software does phasing based on the Hidden Markov Model for haplotypes.  
Pathway analysis for SNPs was performed using SNP ratio test (O'Dushlaine et 
al., 2009). This program calculates the empirical P-values for individual pathways 
based on permutation tests. In short, the phenotype is permuted one hundred times 
and then association analysis is done using the permuted phenotypes. The original 
association results are then annotated into KEGG pathways and compared to the 
permuted results that are also annotated into KEGG pathways.   
In order to study the power of the GenMets sample in GWA for sleep duration 
(I), we performed genetic power calculation using the Genetic Power Calculator 
(Purcell et al., 2003). The power was calculated for an additive model assuming 
quantitative trait locus (QTL) variance of 1.5%, 5% minor allele frequency and 
perfect linkage disequilibrium between QTL and the marker. 
For the candidate gene studies in II and III in the population data, linear or 
logistic regression analysis with additive model and with relevant covariates (age, 
gender and BMI) or chi-square test (III) was performed using the PLINK software 
(http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell et al., 2007). Sleep duration 
was normally distributed (II). Other quantitative traits (TG, TC, HDL-C, LDL-C and 
Epworth sleepiness scale) were squared in order to obtain normal distribution (II). 
For case control analysis of the dichotomous traits (depression and sleep 
disturbances), normalization was not done (III).  Bonferroni correction was used in 
order to adjust for multiple testing (II, III).  
For family-based analysis of the candidate SNPs (IV), we used fbat for 
dichotomous phenotypes (www.biostat.harvard.edu/~fbat) (Horvath et al., 2004) and 
QTDT for quantitative phenotypes (Abecasis et al., 2000). To complement the 
QTDT test, Plink was used to analyze the direction of association for quantitative 
traits using option qfam-total. Age, gender and disease status were used as 
covariates in the analyses of the quantitative traits (IV). No normalization or 
correction for multiple testing was performed in study IV.  
The softwares summarized in Table 4 were used to analyze the genetic markers 
and RNA expression.  
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4.4.2.1 Analysis of RNA Expression  
The significance at the single transcript level was calculated using 2-way 
ANOVA, using control and case groups as one axis and time point as another axis 
(baseline, deprivation and recovery) using (R/Bioconductor open software packages; 
http://www.r-project.org) (II). In addition, changes from baseline to deprivation 
were calculated with the Student’s T-test within the case groups. 
In order to analyze enriched pathways in the RNA expression level (unpublished 
results) an in-house developed pathway analysis program, CIGA, was used 
(Pietilainen et al., 2008). Often individual transcripts that belong to the same 
biological pathway do not reach statistical significance alone. Thus we used an in-
house developed pathway analysis program for RNA expression that calculates a 
cumulative P-value for those transcripts that belong to the same GO and permutated 
the significant pathways with 1,000 in order to adjust for multiple testing. The 2-
way ANOVA was calculated using control and cases groups as one axis and time 
point as another axis (baseline, deprivation and recovery).  The genes were ranked 
for the pathway analysis program by sorting them based on the significance from 2-
way ANOVA. The pathway analysis program calculates the P-value by answering 
the question: "how likely is it to see this many genes (k) that belong to the studied 
pathway this high-up in the ranked list of genes (j), when there are altogether t genes 
that belong to the pathway amongst n genes in the experiment".  
 
 
 
 
The pathway analysis programs rely on the correct annotation of the genes into 
the pathways. Thus, it is often the case that different analysis methods and 
annotations find different pathways for a distinct data set. In order to control for 
annotation problems we verified the detected pathways with two independent 
programs IPA (Ingenuity Systems®, www.ingenuity.com) and Anduril (Ovaska et 
al., 2010). 
For analysis of RNA expression levels in DILGOM population sample, linear 
regression was used with relevant covariates (age, gender and principal components 
correcting for population stratification). The analysis was performed using R version 
2.14.2, http://www.R-project.org/. 
4.4.2.2 Correction for Multiple Testing 
Genetic studies produce a large amount of tests that create false positive results if 
only nominal P-values are considered. In the genome-wide setting (I) we used  
P<10-8 as significance threshold and assigned the empirical P-value by permutation. 
In studies II and III, Bonferroni correction was used in order to adjust for multiple 
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testing (Dunn, 1961). Study IV was performed as follow-up for previous GWA 
studies and association analysis (Baum et al., 2008a, Baum et al., 2008b, Ferreira et 
al., 2008, Sklar et al., 2008, WTCCC, 2007). No correction for multiple testing was 
done in study IV.  
Table 4. Summary of the software used in the analysis of the data 
Analysis Software Reference Study 
Association analysis PLINK Purcell et al., 2007 I-IV 
QTDT fbat Horvath et al., 2004 IV 
Haplotype analysis Haploview Barrett et al., 2005 I 
Phasing Beagle Browning  et al., 2011 I 
Pathway analysis for SNPs SNP ratio test O’Dushlaine et al., 2011 I 
Power calculations 
Genetic power 
calculator 
Purcell et al., 2003 I 
Pathway analysis for RNA 
expression 
CIGA Pietilainen et al., 2008 I 
Epidemiological analyses 
General linear model 
SPSS IBM II 
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5 Results and Discussion 
5.1 Genetic Findings in Normal Sleep Duration (I) 
Sleep duration is a heritable trait (Partinen et al., 1983) but only one common variant 
in ABCC9 by the time of writing this thesis in August 2012 is known to associate 
with normal sleep duration in humans (Allebrandt et al., 2011). We aimed to 
characterize common genetic variants at a single SNP level that associate with sleep 
length by studying a Finnish population-based sample (N=1,941). We then wanted 
to elucidate the genetic pathways that are associated with sleep duration by using 
pathway analysis. The 32 variants showing suggestive evidence for association in 
the discovery sample were followed up in a sample comprising altogether 6,834 
individuals from four Finnish cohorts. The three variants showing nominal 
association of P<0.05 in the follow-up sample were studied further in order to gain 
knowledge of their functional role in sleep regulation with RNA expression analysis 
on sleep duration using a population-based sample and with RNA expression 
analysis in an experimental sleep restriction sample of healthy men that was 
performed in controlled laboratory conditions.  
In order to gain information of the power to detect genome-wide significant 
association (P<5*10-8) in the discovery sample, we performed power calculations 
using an additive model for genetic variants. These calculations were based on the 
assumption that the associating variant would explain 1.5% of the total trait 
variation and allele frequency over 5% in the sample of 1,941 individuals. Perfect 
LD between the marker and the causative variant was also assumed. The 
calculations evidenced that we had limited power to detect variants with genome-
wide significance with only 49% power. 
We then performed genome-wide association analysis on sleep duration. In order 
to visualize the findings, a quantile-quantile (QQ)-plot of the  
–log10 P-value distribution (observed P-values vs. expected P-values) was plotted 
(Figure 9). We observed no deviation from the expected P-value distribution, 
suggesting that none of the findings were more significant than what would be 
expected by chance. Similarly, none of the lowest P-values were significant at the 
genome-wide level as all SNPs had P-values larger than the genome-wide 
significance threshold of P<5*10-8. The SNPs and their suggestive association with 
sleep duration with P-values up to 5*10-5 are shown in Table 5.   
Previous GWA studies have shown that also variants reaching only suggestive 
levels of significance may be biologically relevant (Lango Allen et al., 2010). A 
number of interesting candidate genes were found in vicinity of the variants that 
associated tentatively to sleep duration in GWAS, including glutamate receptors 
(GRID1 and GRIA1), protein tyrosine phosphatases (PTPRU and PTPRT) and 
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KLF6. Genes from the glutamatergic system, such as GRIA3, have been shown to 
associate with sleep duration in candidate gene studies (Utge et al., 2011) and GWA 
studies with sleep disorders such as restless legs syndrome have found significant 
associations with variants in PTPRD, another member of the protein tyrosine 
phosphatase family (Schormair et al., 2008). Moreover, KLF6 is an activator of 
iNOS signaling, which regulates sleep homeostasis (Warke et al., 2003). The 
variants showing suggestive evidence for association (i.e. P<5*10-8 x <5*10-5) were 
thus selected for follow-up in larger sample of Finnish individuals (N=6,834) to 
further study their association with sleep duration. 
Altogether three out of 32 SNPs showed  association to the same direction as in 
the discovery sample of point wise P<0.05 in the follow-up sample. The variants 
were located near PTPRU, KLF6 and between CENTD1 and PCDH7. The minor 
allele A of PTPRU SNP rs10934351 (β=0.037, SE=0.019, P=0.049, MAF=0.027), 
and of SNP rs1037079 between CENTD1 and PCDH7 associated with longer sleep 
duration (β=0.045, SE=0.018, P=0.011, MAF=0.10) whereas the minor allele of 
rs2031573 near KLF6 associated with shorter sleep duration (β=-0.037, SE=0.019, 
P=0.044, MAF=0.11). These findings may support the role of these genes in sleep 
regulation. However, as the findings do not sustain correction for multiple testing 
further association studies on sleep duration are needed to verify the association 
signals and to detect other variants that contribute to sleep duration.  
PTPRU belongs to a protein tyrosine kinase receptor family. It is an interesting 
candidate gene since polymorphisms in PTPRD have been associated with restless 
legs syndrome (Schormair et al., 2008). In order to study whether the associating 
SNP at the vicinity of PTPRU is related to the PTPRU gene itself, we performed a 
haplotype analysis. The relatively rare variant rs10914351 (MAF=0.027) tagged a 
38kb haplotype in the discovery and in the replication data sets. The haplotype was 
unique to the minor allele carriers and was not observed in anyone else in the data 
set (Figure 10). However, the haplotype did not reach the PTPRU gene suggesting 
that the marker rs10914351tags some other functional elements in that area that may 
be responsible for the association with sleep duration rather than direct variation in 
the coding region of the PTPRU gene itself. 
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Figure 9. Quantile-Quantile plot from P-values plotted observed vs. expected. 
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Table 5. GWA-study of sleep duration. Original association signals for sleep 
duration, A1=associating allele, BP=base pair, β=linear regression beta. 
CHR SNP BP A1 BETA SE L95 U95 P Gene 
9 rs974484 78912590 A -0.1101 0.02259 -0.1544 -0.06584 1.18E-06 FOXB2-VPS13A 
3 rs10934301 116858662 G 0.1054 0.02256 0.06122 0.1496 3.16E-06 GAP43 
9 rs4548251 78953578 A -0.1034 0.02254 -0.1476 -0.05925 4.76E-06 FOXB2-VPS13A 
9 rs7869751 78953741 G -0.1029 0.02253 -0.1471 -0.05876 5.24E-06 FOXB2-VPS13A 
1 rs6699898 245329248 A 0.09885 0.02257 0.05463 0.1431 1.25E-05 ZNF669 
8 rs4977188 145028452 A 0.09865 0.02256 0.05442 0.1429 1.30E-05 EPPK1 
10 rs2031573 3991897 A -0.0979 0.02254 -0.142 -0.05367 1.49E-05 KLF6 
10 rs10886445 121052058 G 0.09723 0.02255 0.05304 0.1414 1.69E-05 GRK5 
10 rs12762433 86910260 A 0.09604 0.02261 0.05173 0.1404 2.26E-05 GRID1 
10 rs11591606 16951121 A 0.09522 0.0225 0.05113 0.1393 2.42E-05 CUBN 
5 rs294704 152499281 C -0.0949 0.02246 -0.1389 -0.05087 2.50E-05 NMUR2-GRIA1 
11 rs2073848 113557114 G -0.0949 0.02255 -0.1391 -0.05068 2.70E-05 ZBTB16 
6 rs9349461 49035104 A 0.0946 0.02249 0.05051 0.1387 2.72E-05 ---- 
10 rs10882611 97284803 A -0.0954 0.02273 -0.1399 -0.05082 2.84E-05 SORBS1 
1 rs10914351 30006618 A 0.09408 0.02247 0.05004 0.1381 2.96E-05 PTPRU 
10 rs11188346 97279982 A -0.0951 0.02272 -0.1396 -0.05053 3.00E-05 SORBS1 
10 rs1891787 132798458 A -0.0943 0.02254 -0.1385 -0.0501 3.01E-05 TCERG1L 
6 rs4506041 49083621 A 0.09386 0.0225 0.04976 0.138 3.17E-05 ---- 
14 rs879981 93563662 C 0.09349 0.02244 0.0495 0.1375 3.24E-05 OTUB2 
10 rs7072549 86841405 G 0.09405 0.02259 0.04978 0.1383 3.26E-05 FAM190B-GRID1 
10 rs10509508 86842628 A 0.09405 0.02259 0.04978 0.1383 3.26E-05 FAM190B-GRID1 
4 rs6819546 4902880 G 0.09309 0.02245 0.04908 0.1371 3.53E-05 MSX1 
5 rs13185914 152755844 A -0.0931 0.02246 -0.1371 -0.04904 3.57E-05 GRIA1 
17 rs933534 52925956 G 0.09327 0.02253 0.0491 0.1374 3.63E-05 MSI2 
1 rs2065954 150587968 C 0.09311 0.02252 0.04898 0.1372 3.70E-05 FLG2 
5 rs1429736 117983469 G 0.09303 0.02252 0.04889 0.1372 3.76E-05 ---- 
15 rs4102572 19374161 C -0.093 0.02253 -0.1372 -0.04884 3.83E-05 POTEB 
5 rs1147225 32823941 A 0.09277 0.02248 0.04872 0.1368 3.83E-05 NPRC 
4 rs1037079 32233946 A 0.09248 0.0226 0.04819 0.1368 4.45E-05 PCDH7-CENTD1 
1 rs6673408 196875928 A 0.0919 0.02249 0.04781 0.136 4.58E-05 PTPRC 
1 rs7521839 150651383 G 0.09165 0.02249 0.04756 0.1357 4.80E-05 CRNN 
22 rs5746492 16773933 G -0.0917 0.0225 -0.1358 -0.04755 4.83E-05 MICAL3 
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A rs10914351-rs12058382
B rs995197-rs10914351
C rs995197-rs12058382
PTPRU haplotype
 
Figure 10. Two common haplotypes from the PTPRU variant rs10914351 were observed: A 
and B. The minor allele tagged a longer 38kb haplotype ranging from rs995197 to 
rs12058382 (C) that was not observed in anyone else in the data set.  
5.1.1 RNA Expression Analysis of Follow-up Variants 
During the time this study was performed, RNA expression data was collected from 
the DILGOM sample that was part of the follow-up for the GWAS variants. In 
addition, a collaborative project together with the Institute of Occupational Health 
was performed to study the effects of sleep restriction on RNA expression levels in 
blood leucocytes. We thus studied the effect of the three SNPs that showed point 
wise association in the follow-up sample and their nearest genes (PTPRU, CENTD1, 
PCDH7 and KLF6), performing (1) RNA expression analysis of sleep duration in 
the DILGOM sample and (2) by assessing the change in RNA-expression levels 
caused by experimental sleep restriction carried out in controlled laboratory 
conditions. We hypothesized that the expression levels of genes that regulate sleep 
duration would change if sleep is restricted. 
Expression analysis in the DILGOM sample (N=518 with complete data) 
revealed no eQTLs with rs10914351 and PTPRU. The major allele of rs1037079 
between PCDH7-CENTD1 and the minor allele of rs2031573 near KLF6 that 
associated with shorter sleep in GWAS, increased the respective gene expression 
(PCDH7/ILMN_1710544: β=-0.035, SE=0.017 P=0.039, KLF6/ILMN_1700727: 
β=0.040, SE= 0.020, P=0.042).  Even though these findings were not considered 
statistically significant as they did not sustain correction for four tests (analysis of 
illumine probes ILMN_1657128 and ILMN_2383300 for PTPRU expression, 
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ILMN_1709360 for CENTD1 expression, ILM_1710544 for PCDH7 expression and 
ILMN_1700727 for KLF6 expression from Illumina HumanHT-12 Expression 
BeadChips), the variants showed a nominal association with the respective gene 
expression. Higher expression of KLF6 was also related to shorter sleep length 
(KLF6: β=-0.59, SE=0.36, P= 0.030) (Figure 11A). These findings suggest that 
variants rs1037079 and rs2031573 may be eQTLs for their nearest genes. The lack 
of eQTLs with PTPRU may be reflected by the low allele frequency (<5%), and thus 
a small number of individuals carrying minor allele in the DILGOM RNA 
expression study (N=23). The RNA expression study was also performed in blood 
lymphocytes which may limit the detection of changes in RNA expression since the 
transcripts may have a brain specific function. 
In order to characterize in more detail the role of KLF6 in regulation of sleep, we 
studied its expression changes in an independent sample that was not part of the 
GWAS analysis. In this study sleep was restricted and the study was performed in 
controlled laboratory conditions in healthy young males in order to minimize 
confounding factors. We observed that similarly to population RNA expression, the 
RNA expression of KLF6 was increased after sleep restriction (P=0.006, FC=1.4, 
1555832_s_at transcript for KLF6 from Affymetrix GeneChip Human Genome 
U133 Plus 2.0), suggesting that shorter sleep duration is sufficient to induce KLF6 
expression (Figure 11B). Despite the relatively large variability of the individual 
responses after the sleep restriction, we observed that all nine study participants with 
data available showed increased KLF6 expression after sleep restriction (Figure 
11C).  
We hypothesized that the increase in KLF6 expression might associate with 
changes in sleep intensity (amount of slow wave sleep), measured by EEG, which is 
one of the most heritable traits in humans (De Gennaro et al., 2008). Finally we 
studied the association of KLF6 expression levels and amounts of slow wave sleep. 
We observed a positive correlation between KLF6 expression and the amount of 
SWS (P<0.05 for 1555832_s_at, unpublished observations) further supporting the 
role of KLF6 in sleep regulation.  
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Figure 11. KLF6 in the sleep length groups in DILGOM population sample (A).  KLF6 
expression levels after experimental sleep restriction (B) where the sleep 
restriction values are normalized to baseline and the recovery expression values 
are compared to sleep restriction. The fold change from experimental sleep 
restriction comparing baseline to sleep restriction are shown at the individual level 
(C), baseline = 1. 
The findings of the KLF6 RNA expression study should be considered in the 
light of following limitations. The original eQTL analysis was performed in the 
same population sample (DILGOM) that was also used for the follow-up sample for 
the variants of sleep duration, and the signal for eQTL did not sustain correction for 
multiple testing. The sleep restriction study was also small, with 9 cases and 4 
controls, albeit the number of confounding factors was minimized by careful 
selection of the study participants for age and regular sleep-wake cycle, with 7 to 9 
hours habitual sleep duration. Out of the 54,675 transcripts (for 20,502 genes) that 
can be measured by the Affymetrix GeneChip, the levels of 4,014 were changed 
with P<0.05 after the sleep restriction of 5 nights. According to GeneSpring v.10 the 
expected number of changes would have been 2733. Similarly, with P<0.01 we 
observed 911 changed transcripts whereas 546 transcripts would have been expected 
to change expression by chance. Thus approximately 40% of the transcripts with 
similar significance level as KLF6 (P<0.01) were estimated to be true positive 
findings. This means that we still had 60% probability of finding a false positive 
association by chance. However, the KLF6 levels associated to short sleep both in 
the DILGOM sample and in the experimental sleep restriction sample. In addition, 
the findings on association of increased KLF6 levels with higher amount of SWS, 
reflecting sleep intensity, further support the association of increased KLF6 
expression levels with shorter sleep duration.  
It should also be considered to what extent the changes observed in RNA 
expression measured from blood leukocytes reflect the changes relevant to sleep. It 
has also been shown that sleep affects the functions of all tissues of the body that 
have been tested so far, including blood leukocytes (Irwin et al., 2006, van Leeuwen 
et al., 2009). In addition, the circadian pacemaker genes are present in all cells of the 
body, keeping the cells in sync with the suprachiasmatic nucleus (Cuninkova and 
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Brown, 2008). Sleep has been found to have a strong influence on immune functions 
since shorter sleep changes the strength of the immune response (Spiegel et al., 
2002). Some studies have also shown that immune cells would reflect the expression 
changes observed in the central nervous tissue to some extent. However, the 
observations from tissues that are not the direct targets for any phenotype should be 
interpreted with caution. 
To summarize, the consistently most significant findings in study I were 
observed with one variant near KLF6, which encodes a Kruppel-like transcription 
factor. Increased KLF6 expression correlated with shorter sleep duration both at the 
level of population and in an experimental study of sleep restriction. Our findings 
suggest that KLF6 expression increases as response to short, potentially insufficient 
sleep.  KLF6 has been shown to function in cell division and growth.  Mutations in 
KLF6 in cancers suggest that it has a role as a tumour suppressor, and previous 
association studies have found that KLF6 variants associate with prostate cancer. 
Interestingly, the only study on prostate cancer risk and sleep length showed lower 
disease risk in those individuals having long sleep lengths of over 9 hours (Kakizaki 
et al., 2008). KLF6 is also expressed in the brain: in the cerebral cortex, 
hippocampus, septum, amygdala, basal ganglia, thalamus, and hypothalamus of 
mice (Jeong et al., 2009). These findings of KLF6 on SWS are interesting in light of 
previous studies showing that KLF6 has a binding site in the promoter for inducible 
nitric oxidase (iNOS), which can activate iNOS RNA expression and increase the 
amount of iNOS also in the protein level (Warke et al., 2003). Production of nitric 
oxide, through activation of iNOS, is increased during sleep deprivation in rats, 
which has been shown to be a key step in the induction of recovery sleep (Kalinchuk 
et al., 2006). Our findings are consistent with that KLF6 may have a role in sleep 
duration via iNOS mediated action on SWS amount. 
5.1.2 Pathway Analysis of Sleep Duration 
In order to get a broader view of what changes are related to sleep duration, we 
performed pathway analysis from the GWA study discovery sample. Pathways have 
been shown to explain more of the genetic variation than the individual GWAS 
findings in the pathway alone (Lango Allen et al., 2010), which encouraged us to 
also study the pathways formed by the individual SNPs in sleep duration. We used 
the SNP ratio test. This program compares the actual association signals with those 
that are obtained with randomized phenotypes and annotates the overrepresented 
genes into KEGG pathways. Altogether eight pathways with permuted P<0.05 were 
observed. The pathways enriched with sleep duration are presented in Table 6. The 
results from pathway analysis are always dependent on the correct annotation to the 
pathways. We thus confirmed that similar association signals were also obtained 
with another pathway program, Ingenuity Pathway Analysis.   
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The following pathways were found to be related to sleep duration based on SNP 
pathway analysis and replicated with Ingenuity pathway analysis (IPA): Natural 
killer (NK) cell mediated cytotoxicity (in IPA: NK signaling), Inositol metabolism 
(in IPA: D-myo-inositol-5-phosphate Metabolism) and Long term (synaptic) 
depression (in IPA: Long term synaptic depression). Genes in these pathways may 
contribute to normal sleep duration. 
The NK cell mediated cytotoxicity pathway most likely presents a pathway that 
may be related to the pathological states associated with sleep duration, like short 
sleep or insufficient sleep. It has been previously shown that the amount of NK cells 
is reduced after sleep restriction, whereas proatherogenic interleukins are increased 
(van Leeuwen et al., 2009). As part of the population having short sleep duration 
comprises of natural short sleepers and the other part suffers from insufficient sleep, 
immunological pathways may be important in regulating the interplay between 
normal sleep duration and insufficient sleep. 
In addition, GRIA3 was observed in the long-term (synaptic) depression pathway. 
Variants from GRIA3 have been previously associated with sleep duration in 
candidate gene studies (Utge et al., 2011). Even though the pathway ABC 
transporters were not replicated in IPA, it is interesting to speculate its role in sleep 
regulation. This pathway included a variant in ABCC9, which is so far the only gene 
that has been found in GWAS on sleep duration (Allebrandt et al., 2011).  
It should also be noted that half of the individuals from the discovery sample had 
metabolic disorder. Such a selection in the discovery sample can bias the findings 
even though metabolic disorder was included as a covariate in the original analysis. 
However, distinct pathways, such as long-term (synaptic) depression, suggest a 
more specific role for the genes in this pathway for sleep regulation. Long term 
synaptic depression has also been proposed to be the mechanism in sleep-dependent 
memory consolidation that previously has been proposed to be one of the functions 
of sleep (Yang et al., 2012).  
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Table 6. Pathway analysis of sleep duration. The pathways from KEGG database 
(SNP Ratio Test) are shown. P-values reflect the ratio of pathways obtained from 
association analysis with permuted GWA-studies compared to the original GWAS. 
The pathways that were also significant (nominal association of P<0.05) with IPA are 
bolded. 
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5.1.3 Changes in RNA Expression After Sleep Restriction  
The pathway analysis from GWAS found a NK cell-signaling pathway connecting 
sleep duration with immune functions. In population-based samples, one of the 
challenges in sleep research is to distinguish between normal short sleepers and 
those that are sleep deprived. There is strong epidemiological evidence between 
short sleep duration and insufficient sleep with cardiometabolic diseases and 
mortality (Cappuccio et al., 2010a, Cappuccio et al., 2010b). Sleep restriction and 
total sleep deprivation studies have found defective glucose metabolism and insulin 
signaling after sleep restriction as well as increase in inflammatory markers (Spiegel 
et al., 1999, van Leeuwen et al., 2010), but only one RNA expression study has 
aimed to elucidate the cellular mechanisms behind these changes in humans (Irwin 
et al., 2006). To complement our findings on immunological and metabolic 
pathways in sleep duration, we aimed to characterize the changes induced after sleep 
restriction in transcriptome in a controlled environment from blood leukocytes in 
healthy young males. RNA expression at the whole-genome level from three time 
points was studied: baseline before sleep restriction, deprivation after five nights of 
sleep restriction and only four hours of sleep per night, and finally a recovery after 
two nights with eight hours of sleep. This study was performed to reflect the 
cumulative sleep restriction of a week of extremely hard work.  
5.1.3.1 Sleep Restriction 
Biological networks were studied using the biological Gene ontology (GO) 
pathways that were changed after sleep restriction among all transcripts that had 
passed QC (N=15,101). This was followed by analysis using 2-way ANOVA and 
ranking the transcripts for the pathway analysis program by sorting them based on 
significance. Permutation analysis was done by randomizing the transcription values 
and comparing the original association with the randomized reference in the same 
data set. In addition, the transcripts were divided into up- or down-regulated based 
on their expression in the sleep restriction time point to distinguish between 
activated or inactivated pathways. The findings were verified with two independent 
pathway analysis programs (Anduril and IPA) in the same data set so that both 
produced similar top findings as the original association.  
The up-regulated GOs comprised of enrichment of inflammation and immunity 
related GOs (P<0.0001, P<0.005 after permutation). As expected based on the 
epidemiological findings, we observed the activation of immunity and leukocyte 
pathways, and the activation of cytokine pathways, which together comprised the 
most significant pathways (Table 7). Specifically, the statistically most significant 
were B cell activation and interleukin-8 production pathways (P<0.1*10–4, P 
corrected <0.001). Among the 30 top pathways, genes overlapped considerably (B 
cell activation, leukocyte activation, cell activation, lymphocyte activation, adaptive 
immunity, adaptive immune response, adaptive immune response based on somatic 
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recombination of immune receptors built from immunoglobulin super family 
domains, leukocyte differentiation, and lymphocyte differentiation). A large part of 
the up-regulated pathways were related to the function and regulation of the immune 
system. These included B cell activation pathways. These findings are in line with 
previous observations from the same data set showing that the amount of B cells is 
increased in sleep restriction (van Leeuwen et al., 2009). Of the other lymphocyte 
populations, NK-cells decrease in sleep restriction (van Leeuwen et al., 2009).  
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Table 7. Up-regulated pathways after experimental sleep restriction. The P-
values were calculated as point wise P-values and permutated 1,000 times 
to obtain corrected P-values. The column N genes total shows how many 
genes are annotated in the pathway. N contributing genes tell how many of 
the annotated genes are associating in this data set. 
 
ID Pathway P P perm. 
N 
genes 
total 
N 
contribut
ing genes 
GO:0042113 B cell activation 3.62E-06 0.001 90 43 
GO:0032637 IL8 production 6.49E-06 0.001 9 8 
GO:0001530 lipopolysaccharide binding 6.49E-06 0.001 9 8 
GO:0006805 xenobiotic metabolic process 1.23E-05 0.001 8 5 
GO:0050817 coagulation 1.40E-05 0.001 75 22 
GO:0045321 leukocyte activation 1.77E-05 0.001 208 68 
GO:0001775 cell activation 2.20E-05 0.002 217 70 
GO:0002460 
adaptive immune response based on 
somatic recombination of immune 
receptors 
2.41E-05 0.002 83 51 
GO:0005543 phospholipid binding 2.63E-05 0.003 91 29 
GO:0046649 lymphocyte activation 2.96E-05 0.002 184 61 
GO:0045416 
positive regulation of IL8 biosynthetic 
process 
3.32E-05 0.001 8 7 
GO:0042228 IL8 biosynthetic process 3.32E-05 0.001 8 7 
GO:0045414 regulation of IL8 biosynthetic process 3.32E-05 0.001 8 7 
GO:0015671 oxygen transport 3.61E-05 0.001 10 8 
GO:0005833 hemoglobin complex 3.61E-05 0.001 10 8 
GO:0002250 adaptive immune response 3.74E-05 0.001 88 53 
GO:0002521 leukocyte differentiation 3.89E-05 0.002 110 60 
GO:0009410 response to xenobiotic stimulus 5.10E-05 0.003 10 5 
GO:0005885 Arp2/3 protein complex 6.33E-05 0.001 15 15 
GO:0030098 lymphocyte differentiation 7.09E-05 0.005 93 35 
GO:0007249 I-kappaB kinase/NF-kappaB cascade 8.34E-05 0.003 107 39 
GO:0042108 
positive regulation of cytokine 
biosynthesis 
9.67E-05 0.003 26 19 
GO:0015669 gas transport 0.00011 0.001 11 8 
GO:0007596 blood coagulation 0.00014 0.006 65 15 
GO:0009620 response to fungus 0.00015 0.001 17 10 
GO:0002695 
negative regulation of leukocyte 
activation 
0.00019 0.001 19 9 
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Another group with overlapping genes comprised of six pathways. These were 
interleukin 8 (IL-8) biosynthesis, positive regulation of IL-8 biosynthesis, IL-8 
production, lipopolysaccharide binding, all P<0.001, and positive regulation of 
cytokine biosynthesis P<0.005. The overlap between pathways was expected as GOs 
are built as hierarchical trees where several GOs form a larger ontology. The 
majority of genes in these pathways consisted of toll-like receptors. The xenobiotic 
process (P<0.001) and the response to xenobiotic stimulus (P<0.005) as well as I-kB 
kinase–NF-kB cascade (P<0.005) were also among the significantly enriched. Pro-
inflammatory cytokines have been shown to increase after sleep restriction (Irwin et 
al., 2006, van Leeuwen et al., 2009). These findings complement our results from 
the GWAS pathways and suggest that inflammatory responses are changed after 
sleep restriction. 
A biologically very different set of GOs was observed among the down-regulated 
genes (top 30 pathways presented in Table 8). Several pathways participating in 
lipid transport were enriched: intracellular lipid transport, cholesterol efflux, 
sequestering of lipids, and sterol transporter activity (P<0.001) being the top ranked. 
These changes may reflect a compensatory mechanism for short term sleep 
restriction induced stress as cholesterol levels have been shown to decrease after 
stress response (Choi et al., 2005). These findings are interesting in the light of 
previous finding on epidemiological settings where short sleep duration is related to 
higher circulating blood lipid levels (Kronholm et al., 2011). It is likely that longer 
sleep deprivation has opposite effects on total cholesterol levels than short term 
sleep restriction. 
In addition, the circadian rhythm pathway was down-regulated (P<0.05). The 
down-regulation is unlikely to reflect a phase delay effect that was earlier reported to 
be a modest 16 minutes (van Leeuwen et al., 2010). Rather, it may be caused by 
dampening of the cortisol and circadian rhythm. Such overall lower amplitude in 
circadian gene expression has been previously observed with circadian genes 
(Kavcic et al., 2011). Overall the changes in circadian clock gene expression have 
been connected to energy, lipid and glucose metabolism at a molecular level (Bass 
and Takahashi, 2010). Despite the cause, either in amplitude or expression rhythm, 
this may suggest that the circadian genes are out-of-sync after sleep restriction. It 
has been proposed that asynchrony in the timing of autonomous internal clocks in 
the brain and peripheral tissues might contribute to the development of metabolic 
disease states and experimental studies with shift work and jet lag simulation have 
supported this hypothesis (Huang et al., 2011). 
To summarize, our findings suggest that short sleep duration is related to 
metabolic and immunological changes in transcriptomic level, which may explain 
part of the connection with cardiometabolic diseases and sleep. In addition, SNPs in 
PPAR-signaling pathway and in immunological pathways may predispose to either 
shorter or longer sleep duration either independently or via comorbid diseases. The 
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findings with sleep restriction suggest that inflammatory responses may be 
responsible for some of the changes seen after shorter sleep duration. In addition, 
metabolic balance may be changed after sleep restriction. 
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Table 8. Down-regulated pathways after experimental sleep restriction. The P-
values were calculated as point wise P-values and permutated 1000 times 
to obtain corrected P-values. The column N genes total shows how many 
genes are annotated in the pathway. N contributing genes tell how many of 
the annotated genes are associating in this data set. 
ID           Pathway      P P permuted N genes total 
N 
contributing 
genes 
GO:0032365       intracellular lipid transport       1.71E-05 0.001 9 4 
GO:0015833       peptide transport       0.00015 0.003 20 4 
GO:0015918       sterol transport       0.00018 0.001 8 3 
GO:0055092       sterol homeostasis       0.00018 0.001 8 3 
GO:0030301       cholesterol transport       0.00018 0.001 8 3 
GO:0042632       cholesterol homeostasis       0.00018 0.001 8 3 
GO:0045736       
negative regulation of cyclin-
dependent protein kinase 
activity       
0.00029 0.003 9 5 
GO:0006869       lipid transport       0.00037 0.006 49 6 
GO:0055088       lipid homeostasis       0.00038 0.002 10 3 
GO:0005548       phospholipid transporter activity       0.00039 0.006 14 3 
GO:0005319       lipid transporter activity       0.00049 0.004 25 4 
GO:0015909       long-chain fatty acid transport     0.00058 0.005 9 3 
GO:0008299       isoprenoid biosynthetic process       0.00073 0.004 7 7 
GO:0032393       MHC class I receptor activity      0.00075 0.005 7 6 
GO:0006635       fatty acid beta-oxidation       0.00082 0.01 10 3 
GO:0004715       non-membrane spanning protein tyrosine kinase activity    0.00082 0.011 16 11 
GO:0050680       negative regulation of epithelial cell proliferation       0.00104 0.012 15 3 
GO:0015908       fatty acid transport       0.00111 0.007 11 3 
GO:0009062       fatty acid catabolic process       0.00111 0.008 11 3 
GO:0004860       protein kinase inhibitor activity    0.00117 0.018 19 5 
GO:0016538       cyclin-dependent protein kinase regulator activity       0.00126 0.009 11 5 
GO:0048286       alveolus development       0.00128 0.01 7 4 
GO:0030509       BMP signaling pathway       0.00129 0.011 13 3 
GO:0007623       circadian rhythm       0.00145 0.015 14 12 
GO:0046395       carboxylic acid catabolic process       0.00146 0.006 12 3 
GO:0016054       organic acid catabolic process    0.00146 0.007 12 3 
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5.2 Genetic Connection between Metabolism and Sleep (II) 
Our findings from GWAS pathways and RNA expression in sleep restriction 
prompted us to look in more detail at the connection between cardiometabolic 
diseases and sleep at the epidemiological and at the genetic level. Recently it was 
found that the heritability for BMI and blood lipid composition is higher in 
individuals having short sleep duration (Watson et al., 2010). This can be explained 
in two ways. First, short sleep is a risk environment for BMI or lipid genes and 
second, there may be common genetic variants that predispose both to high BMI and 
lipid levels as well as to shorter sleep duration.  
We characterized the connection between blood lipid levels and sleep duration at 
the population level in a data set that combined two Finnish population samples, 
Finrisk07 and Health 2000. We observed a significant association between lipid 
levels and sleep duration so that both ends of sleep, short and long sleep, had a 
worse lipid profile. This was tested by comparing the sleep duration groups at the 
ends (5 and 6 hours) separately to the rest of the sleep duration groups with 
ANOVA. A similar analysis was also performed separately with the long sleep 
duration groups (9 and10 hours) with the rest of the sleep duration groups (Table 9). 
The association of the high levels of triglycerides (TG), total cholesterol (TC) and 
low levels of HDL-cholesterol was seen in both short and long sleepers, whereas 
LDL-cholesterol was lowest in individuals sleeping nine hours or more (Table 9).  
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Table 9. Association of lipid levels with sleep duration. The association 
between sleep time and lipid variables from Finnish population samples 
Health 2000 and Finrisk 07. Abbreviations: HDL-C, high-density 
lipoprotein; LDL-C, low-density lipoprotein; TC, total cholesterol; TG, 
triglyceride.  
a ANOVA P-value <0.05 indicates significant association with sleep 
duration when comparing the group to all other sleep duration groups 
within the lipid variable.  
b ANOVA P-value <0.01 indicates significant association with sleep 
duration when comparing the group to all other sleep duration groups 
within the lipid variable.  
c ANOVA P-value <0.001 indicates significant association with sleep 
duration when comparing the group to all other sleep duration groups 
within the lipid variable. 
Total 
sleep time 
(hours) 
N TG  mmol l–1±SD 
TC  
mmol l–1±SD 
HDL-C  
mmol l–1±SD 
LDL-C  
mmol l–1±SD 
5 370 1.63±1.04a 5.77±1.08b 1.36±0.41 3.61±1.145a 
6 1327 1.57±1.04a 5.65±1.12a 1.38±0.39 3.51±1.11 
7 4101 1.48±0.97b 5.61±1.11b 1.39±0.38 3.5±1.08b 
8 4472 1.50±0.96 5.57±1.11b 1.39±0.38 3.45±1.09b 
9 1208 1.53±1.00 5.48±1.07c 1.39±0.37 3.37±1.01c 
10 562 1.79±1.28c 5.57±1.20 1.31±0.39c 3.36±1.17a 
Total 12 040 1.52±1.00 5.59±1.11 1.38±0.38 3.47±1.09 
 
We then studied whether there are shared genetic factors that contribute both to 
the regulation of lipid levels and the regulation of sleep duration. We selected 59 
risk variants from GWA studies with blood lipid levels that were published before 
September 2010 when the selection was made (Teslovich et al., 2010) and 
performed association analysis with these variants and sleep duration. Two genetic 
variants associated significantly with sleep duration and the findings sustained 
correction for multiple testing (rs17321515 β=0.081, P=8.92*10-5, Bonferroni 
corrected P=0.0053; rs2954029, P=0.00025, corrected β=0.076, P=0.015). All 
variants with nominal P <0.05 are presented in Table 10.  
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Table 10. Association of lipid gene candidate SNPs with sleep duration. TRIB1 
shows significant association with sleep duration (linear model adjusted for 
age and gender). 
CHR SNP BP MAF BETA P GENE 
8 rs17321515 126555591 G 0.0815 8.92E-05 TRIB1 
8 rs2954029 126560154 T 0.0764 2.46E-04 TRIB1 
1 rs4846914 228362314 G -0.0539 0.0103 GALNT2 
7 rs12670798 21573877 C -0.0582 0.0148 DNAH11 
}11 rs174570 61353788 T 0.0540 0.0301 FADS3/FADS2 
1 rs12740374 109619113 T -0.0505 0.0480 SORT1 
 
The most significant variant, rs17321515 near TRIB1 was supported in an 
independent sample of 2,189 Finnish twins (β=0.063, P=0.022). Meta-analysis of 
the two Finnish data sets further strengthened the association (β=0.073,  
P=8.1*10-6), further supporting the role of TRIB1 in sleep regulation. Analysis of 
genotype groups revealed that the individuals carrying the protective minor allele for 
lower blood lipid levels had longer sleep duration (Figure 12A) and the risk variants 
were more common in shorter sleep duration groups (Figure 12B). The individuals 
carrying risk genotype AA showed association to the same direction (shorter sleep 
duration) in all age groups except for those between 41-50 years (i.e.25-40 years 51-
60 years, 61-70 years, 71-80 years, 81-90 years). Based on OR values it seemed that 
the TRIB1 variant would have a larger effect among older individuals. However, 
excluding individuals that were over 60 years of age did not remove the association 
even though the significance and the effect size after removing these individuals was 
lower (β=0.048, P=0.037) (Figure 12 C). As sleep duration and lipid levels are 
connected in phenotype level it is possible that the effect seen with sleep duration is 
caused by the association with lipid levels. We thus performed the same association 
analysis but adjusted the analysis with blood lipid levels. However, adjusting for 
blood lipid levels did not abolish the association with shorter sleep duration, 
suggesting that TRIB1 had an independent role in sleep regulation as well. Similarly, 
it could be possible that age or comorbidities related to sleep or lipid levels would 
explain the association. We tested this by excluding individuals with sleep problems, 
use of hypnotics and use of lipid medication, which did not abolish the association. 
In contrast, the association was stronger in this group (TG adjusted β=0.082, 
P=7.82*10-5, HDL-C adjusted β=0.084, P=5.77*10-5).   
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Figure 12. Association of TRIB1 rs17321515 genotypes with sleep duration (A) and 
genotype frequencies in different sleep duration groups (B). The association was 
not dependent on age. This is visualized in C where tendency for shorter mean 
sleep duration was observed in all age groups except for those between 41-50 
years for major major (AA) genotype (C). These differences did not reach 
statistical significance in age group level. It seemed that older individuals would 
have larger effect. However, excluding individuals that were over 60 years of age 
did not remove the association.  
Finally, we studied the levels of TRIB1 RNA expression after experimental sleep 
restriction in a separate study in nine healthy volunteers. Functional evidence of 
TRIB1 after sleep restriction showed that the expression of TRIB1 increased 1.6 fold 
on average in sleep restriction (P=0.006, Figure 13). In addition, the baseline 
normalized RNA expression of TRIB1 showed inverse correlation with the baseline 
normalized SWS amount in recovery, suggesting that TRIB1 may have a role in 
SWS regulation. Earlier studies on cholesterol levels both in epidemiological and 
experimental sleep deprivation studies in mice have shown that the transcription of 
genes regulating cholesterol synthesis and lipid transport increase in sleep 
(Giebultowicz and Kapahi, 2010). In addition, sleep deprivation studies performed 
in Drosophila have found a relationship between lipid metabolism and tolerance to 
sleep deprivation, suggesting that changes at the level of enzymes that modulate 
lipid metabolism enzymes alter the response to sleep deprivation (Thimgan et al., 
2010). Based on these data we propose that the association between sleep and lipid 
levels is mediated partially through the same genes such as TRIB1. 
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Figure 13. TRIB1 levels in sleep restriction. TRIB1 mRNA levels in sleep restriction. 
Baseline (BL), sleep restriction (SR) and recovery (REC). BL=1. 
 
TRIB1 is expressed almost in all tissues, with the highest expression being 
observed in the brain, liver and leukocytes (Hidalgo et al., 2009). Hepatic TRIB1 
over expressing mice show lower TG, VLDL, HDL-C, LDL-C levels and APOB 
secretion. In Trib1 knockout animals an opposite lipid profile is observed and 
functional studies suggest the involvement of acetyl-CoA carboxylase 1 (Acc1), 
fatty acid synthase (Fasn) and stearoyl-coenzyme A desaturase1 (Hidalgo et al., 
2009). No studies of the activity or sleep of these animals have been reported so far. 
Our findings suggest that the association between sleep duration and TRIB1 is not 
directly dependent on the effect of TRIB1 on lipids. 
Another protein in tribbles family, TRIB2 has been related to pathogenesis of 
narcolepsy and in another autoimmune disease, uveitis (Cvetkovic-Lopes et al., 
2010, Zhang et al., 2005). Both TRIB1 and TRIB2 also regulate inflammatory 
reactions and Akt and MAPK signaling (Hegedus et al., 2007, Kiss-Toth et al., 
2004, Kiss-Toth et al., 2006). However, they differ also in regard to their cellular 
location: TRIB1 has been detected in the nucleus whereas TRIB2 is a cytoplasmic 
protein. Similarly, in GWA studies TRIB1 is related to energy metabolism and has 
been found in lipid trait and coronary heart disease. In contrast, TRIB2 seems to be 
related to inflammatory reactions and autoantibody production in narcolepsy and 
uveitis. Our findings suggest that TRIB1 variants that associate with both sleep and 
lipid levels may function in normal sleep regulation. One of the aspects of sleep is to 
balance changes in energy expenditure or prolonged waking (Benington and Heller, 
1995). TRIB1 could have an effect in these functions as variants of TRIB1 associate 
TRIB1 in sleep  
 
 Lipid risk variants rs17321515 
and rs2954029 associate with 
shorter sleep duration. 
 TRIB1 expression levels are 
increased after sleep restriction 
 Expression levels show inverse 
correlation with SWS duration 
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with both sleep and lipid metabolism as well as correlate with the recovery SWS 
after sleep restriction. 
 
5.3 Genetic Connection of Depression and Genes Related to 
Adenosine (III) 
Sleep and depression are connected at the epidemiological level and poor sleep 
quality predisposes to depression (Paunio et al., 2009). Individuals suffering from 
depression have specific sleep problems. Depression, like other neuropsychiatric 
diseases, is not clearly one disease. Individuals suffering from depression can have a 
variety of sleep problems like insomnia, or symptoms of insomnia such as early 
morning awakenings as well as fatigue. It is tempting to consider that the same 
genetic variants would control sleep and depression. Moreover, the variants 
affecting depression with early morning awakenings could be distinct from those 
that affect depression with fatigue. We have previously shown that variants in five 
distinct neural networks that are related to depression associate with distinct 
subtypes of depression with either early morning awakenings or fatigue. The 
associating variants are located in glutamatergic (GRIA3, GAD1, P2RX7 and 
DAOA), serotonergic (SLC6A4 and TPH2), neural plasticity (DISC1, CREB1 and 
BDNF) and HPA axis genes (CRHR1) (Utge et al., 2011). In addition, we observed 
that variants in the circadian system, TIMELESS, associate with depression and 
sleep disturbances (Utge et al., 2010). These earlier findings suggest that these 
variants also regulate aspects of sleep in depression.  
Adenosine is one of the best characterized modulators of sleep (Basheer et al., 
2004, Porkka-Heiskanen et al., 1997). It modulates sleep intensity via adenosine A1 
and A2A receptors (Bjorness et al., 2009, Retey et al., 2005, Urade et al., 2003). 
Adenosine can also be used to make adenosine triphosphate that is used for energy 
production (Porkka-Heiskanen et al., 1997). Lack of energy is also a core symptom 
of depression and it has been suggested that a decreased metabolic rate could 
explain these symptoms (Tsiouris, 2005). We hypothesized that impaired synthesis 
or transport of adenosine could be responsible for down-regulation of energy 
production. Here we wanted to elucidate the role of polymorphisms in genes related 
to adenosine and study their role in depression.  
The genes related to adenosine were studied in the depression sample that had 
been selected earlier and included all individuals from the Health 2000 project that 
had a depression diagnosis. The sample comprised of 383 cases and 1,357 controls. 
It was further divided as depression (N=383, 258 females and 125 males), 
depression with early morning awakenings (N=109 females, 61 males) and 
depression with fatigue (N=194 females, 103 males). Altogether 117 SNPs that 
tagged the coding region and 10kb upstream and 10kb downstream of the coding 
region in thirteen genes related to adenosine were studied. The genes selected were 
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adenosine transporters, receptors and metabolic enzymes. Association analysis with 
depression, symptoms of early morning awakenings and fatigue was performed 
separately in both genders. Bonferroni correction was used to correct for multiple 
testing.     
The most significant variant that sustained Bonferroni correction was found with 
depression in females in ENT3 (SLC29A3) with variant rs12256138 (OR=0.68, 
P=0.0004, P corrected = 0.046). The same variant also associated with early 
morning awakenings (OR=0.64, P=0.0033). Since we already genotyped all 
individuals that were diagnosed with depression, we studied the association in 
individuals with early morning awakenings that is a common symptom and risk 
factor for depression. The same variant was associated in the rest of the females 
from Health 2000 with early morning awakenings (OR=0.81, P=0.043, unpublished 
observations). These data suggest that variation in ENT3 may have a role in 
depression and in early morning awakenings, in women.  
No variants sustaining Bonferroni correction was found in the analysis of men. 
Point wise significant findings for both genders were found largely in the ENT 
transporters. However, the only gene that associated in both genders was ADA 
(variant rs6031682 in females and rs452159 for males) that showed point wise 
association with depression and fatigue. Another ADA variant has previously been 
associated with sleep intensity but it was not genotyped in our sample due to 
technical problems. It is noteworthy that females consistently show more significant 
findings in our samples with depression. This may be partially due to larger 
heritability component of depression in females (h2=0.42) compared to males 
(h2=0.29) (Kendler et al., 2006). Another contributing factor is most likely the 
sample size as there were only 109 males diagnosed with depression in the data set 
compared to 258 females. Overall this study is limited by its small sample size. 
Adenosine has previously been related to sleep homeostasis but an increasing 
amount of literature is emerging of the function of adenosine in depression. In 
addition to metabolic rate, adenosine is related to neurotransmitter release, of which 
especially glutamate and dopamine are essential to mood regulation. Depressed 
individuals show increase in cortical glutamate and adenosine is capable of 
increasing extracellular levels of glutamate (Boison et al., 2009). Originally we 
hypothesized that adenosine may be involved in this process via its receptors or via 
its synthesis. Our current findings suggest however, that variation in the ENT 
transporters that regulate the levels of intra- and extracellular adenosine may play a 
larger role in the connection between depression and adenosine. However, with the 
current findings and the small data set, this hypothesis remains speculative. Together 
these findings suggest that adenosine may be related to depression with sleep 
disturbances and depression alone. In summary with our previous findings on 
circadian genes in mood regulation, we can conclude that both circadian and 
homeostatic factors have an effect on depressive disorder, sleep disturbances and 
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normal sleep duration. It is also the same variants that mediate all these traits, 
suggesting that mood and sleep regulation are connected at the genetic level as well. 
 
5.4 Circadian, Seasonal and Cognitive Performance 
Associates with Bipolar Disorder Risk Variants (IV) 
We previously studied the association of 26 SNPs that showed promising 
association with BD (Baum et al., 2008a) in a Finnish Bipolar family sample of 723 
individuals from 180 families (Ollila et al., 2009). The previous association analysis 
concentrated on BD. The previous study as well as the current study described 
below, included variants that were not genome-wide significant in the discovery 
samples. Such suggestive signals were, however, interesting candidate variants and 
were included in the studies since only one variant for BD with genome-wide 
significance had been detected at the time when these studies were performed. As 
also discussed in study I, the variants with suggestive association can be of 
biological relevance.  
In the present study, we aimed to include variants from two additional GWA-
studies (Sklar et al., 2008, WTCCC, 2007). In the present study analysis of 
additional quantitative intermediate phenotypes for bipolar disorder 
(endophenotypes) that were not included in the previous study, were analyzed in the 
same Finnish Bipolar family sample. In addition, association analysis with BD was 
performed for those variants that were not studied in the earlier study in the Finnish 
sample for BD. Two suggestive associations with BD in the Finnish bipolar sample 
were observed in the current study (point wise P<0.05). The variants were located at 
the vicinity of LPIN1 (rs4027132) and CDH7 SNPs with high LD (r2>0.8 for all 
variants, from rs2850699, rs2850700, rs2850701, rs2658046, rs976882, rs12970791 
and rs1444067). The variants associated in the previous study were at the vicinity of 
SORCS2 (rs4411993, rs7683874, rs10937823), DFNB31 (rs10982256) and 
SLC39A3 (rs4806874). The variants in SORCS2 region were not in LD with each 
other (r2<0.80). The associations from the present study and from the previous study 
(Ollila et al., 2009) are shown in Table 11.  
Previous studies have shown that circadian and seasonal rhythms are often 
disturbed in BD and changes in these rhythms can induce mania (Jackson et al., 
2003). We hypothesized that the same variants that contribute to BD would have an 
effect on sleep or cognitive endophenotypes for BD. We thus selected the 13 
variants that were associated with BD in the Finnish Bipolar family sample (Ollila et 
al. 2009, study IV) and studied their association with chronotype, seasonality and 
various domains of cognition. The latter included 22 neuropsychological test 
variables from the Wechsler Adult Intelligence Scale Revised (WAIS-R), the 
Wechsler Memory Scale Revised (WMS-R), the California Verbal Learning Test, 
the Stroop Color and Word Test, and the Controlled Oral Word Association Test. 
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Analyses with seasonal, circadian and cognitive phenotypes were adjusted for age, 
gender and BD in order to remove the association signal coming from the disease. 
The association results for the seasonality traits measured as seasonal changes in 
sleep duration, social activity, mood, energy level, weight and appetite are presented 
in Table 12. The associations with the neurocognitive test variables with point wise 
P<0.05 are presented in Table 13. 
The strongest association signals for the quantitative endophenotypes were 
obtained with the variant from the previously published replication study in the 
Finnish bipolar family sample (Ollila et al., 2009), which in the present study 
associated with seasonal change in sleep duration DFNB31 (rs10982256, point wise 
P=0.005). DFNB31 SNP rs10982256 was also the only SNP that sustained 
correction for multiple testing in the previously reported replication analysis for BD 
(Ollila et al., 2009).  
Variants in the region of CDH7  showed association with seasonal and circadian 
phenotypes as well as with those cognitive tests that were related to visual working 
memory and visual attention (P<0.01). The most consistent findings were observed 
with variant rs2850701. Interestingly, the same variants that associated suggestively 
with increased BD also associated with better performance in visual memory and 
attention. The function of CDH7 is related to brain development (Luo et al., 2004) 
and animal studies have shown that it is expressed in the developing eye and retina 
(Faulkner-Jones et al., 1999). Our findings suggest that variants in CDH7 are related 
to phenotypes that process visual information such as circadian and seasonal 
changes in light-dark transitions. The study also shows that same variants that 
predispose to BD may also be beneficial for other traits, such as visual memory or 
attention. Our findings are consistent with the hypothesis that variants predisposing 
to psychiatric diseases may have an evolutionary advantage. However, these 
findings should be interpreted with caution since they were not genome-wide 
significant in the original discovery samples and were not adjusted for multiple 
correction in the Finnish data set. 
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Table 11. Association with BD and mood disorders. Association with previously 
associated variants with BD in SORCS2, DFNB31 and SLC39A3 by Ollila 
et all 2009 and associations in the present study LPIN1 and CDH7. 
BD=BD type I. Mood= any mood disorder. Variants within CDH7 measure 
the same signal (r2>0.8 for all variants). Variants within SORCS2 measure 
different signals (r2<0.80). Positive Z-values indicate association of the 
minor allele. 
Gene SNP GWAS Maj/Min MAF Z P BD Z 
P 
MOOD 
LPIN1 rs4027132B WTCCC A/G 0.34 −2.03 0.042 −1.80 0.071 
SORCS2 rs4411993A Baum et al., 2008 C/T 0.19 2.75 0.006 2.46 0.014 
SORCS2 rs7683874A Baum et al., 2008 G/A 0.12 2.49 0.013 2.61 0.009 
SORCS2 rs10937823A Baum et al., 2008 C/T 0.11 2.86 0.004 2.83 0.005 
DFNB31 rs10982256A WTCCC C/T 0.44 2.58 0.01 3.23 0.001 
CDH7 rs2850699B Sklar et al., 2008 T/G 0.37 −2.34 0.019 −2.20 0.028 
CDH7 rs2850700B Sklar et al., 2008 C/T 0.38 −2.52 0.012 −2.32 0.021 
CDH7 rs2850701B Sklar et al., 2008 T/G 0.38 −2.46 0.014 −2.08 0.038 
CDH7 rs2658046B Sklar et al., 2008 T/C 0.37 −2.31 0.021 −1.76 0.078 
CDH7 rs976882B Sklar et al., 2008 G/A 0.36 −2.24 0.025 −2.06 0.039 
CDH7 rs12970791B Sklar et al., 2008 G/T 0.36 −2.01 0.044 −1.66 0.097 
CDH7 rs1444067B Sklar et al., 2008 C/A 0.38 −2.37 0.018 −2.27 0.023 
SLC39A3 rs4806874A Baum et al., 2008 A/G 0.41 −2.12 0.034 −1.13 0.259 
A Association with BD reported in Ollila et al 2009 
B Selected for the current study IV 
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Table 12. Association with seasonality phenotypes: change in sleep duration, 
social activity, mood, weight and appetite between seasons. The associations 
with traits showing point wise association of P<0.05 are shown. Association with 
chronotype (mornigness eveningness), seasonal changes in social activity, mood, 
weight, appetite and energy levels. Positive Z values indicate association of minor 
allele and negative values indicate association of major allele. 
 
    Seasonality 
    Sleep duration Social activity Mood Weight 
Gene SNP Z P Z P Z P Z P 
LPIN1 rs4027132 -1.025 0.305 -0.867 0.386 -0.735 0.462 -1.939 0.05
SORCS2 rs4411993 1.263 0.207 -0.168 0.866 0.664 0.507 -0.775 0.43
SORCS2 rs7683874 -1.996 0.046 — — — — — —
SORCS2 r 10937823 1.996 0.046 — — — — — —
DFNB31 rs10982256 2.784 0.005 1.615 .106 2.588 0.010 2.674 0.00
CDH7 rs2850699 -1.743 0.081 -2.099 0.036 -1.863 0.062 -1.740 0.08
CDH7 rs2850700 -2.011 0.044 -2.244 0.025 -2.095 0.036 -1.694 0.09
CDH7 rs2850701 -2.026 0.043 -2.384 0.017 -2.200 0.028 -1.844 0.06
CDH7 rs2658046 -1.689 0.091 -2.108 0.035 -1.761 0.078 -1.664 0.09
CDH7 rs976882 -1.644 0.100 -2.017 0.044 -2.148 0.032 -1.657 0.09
CDH7 rs12970791 -1.521 0. 28 -1.897 0.058 -2.102 0.036 -1.397 0.16
CDH7 rs1444067 -1.793 0.073 -2.017 0.044 -2.148 0.032 -1.833 0.06
SLC39A3 rs4806874 0.549 0.583 0.351 0.726 1.335 0.182 0.703 0.48
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Tabl  13.  Association of bipolar candidate SNPs with intermediate phenotypes 
verbal working memory, visual attention and visual working memory. 
Positive β values indicate association of minor allele. Associations with 
with point wise P< .05 are shown. 
Gene SNP β P Plink P QTDT β P Plink P QTDT β P Plink P QTD
LPIN1 rs4027132 1.246 0.037 0.061 -0.313 0.214 0.045 -0.287 0.352 0.140 
SORCS2 rs4411993 0.865 0.250 0.287 0.177 0.523 0.741 0.094 0.766 0.945 
SORCS2 rs7683874 -0.359 0.698 0.649 -0.347 0.309 0.179 -0.048 0.901 0.717 
SORCS2 rs10937823 -0.359 0.698 0.652 -0.404 0.241 0.168 -0.126 0.748 0.668 
DFNB31 rs10982256 -1.094 0. 62 0.091 -0.164 0.4 5 0.753 0.044 0.844 0.634 
CDH7 rs285069  -1.144 0.053 0.035 -0.648 0.013 0.008 -0.627 0.050 0.020 
CDH7 rs285070  -1.170 0. 57 0.040 -0.667 0.011 0.010 -0.657 0.043 0.019 
CDH7 rs2850701 -1.172 0.053 0.039 -0.687 0.010 0.006 -0.673 0.040 0.017 
CDH7 rs2658046 -1.146 0.058 0.053 -0.663 0.013 0.009 -0.636 0.052 0.019 
CDH7 rs976882 -1.137 0. 59 0.047 -0.683 0.0 8 0.006 -0.656 0.042 0.019 
CDH7 rs12970791 -1.328 0.022 0.010 -0.547 0.034 0.016 -0.577 0.069 0.022 
CDH7 rs1444067 -1.147 0.055 0.042 -0.684 0.010 0.006 -0.667 0.041 0.016 
SLC39A3 rs4806874 0.219 0.683 0.665 -0.025 0.901 0.620 0.415 0.068 0.261 
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6 Concluding Remarks and 
Future Prospects 
This thesis aimed to characterize genetic variants that on the first hand contribute to 
normal sleep duration and on the other hand relate sleep duration and sleep 
disturbances with co-morbidities. In addition to a traditional GWA study a 
functional approach was used that combined RNA expression in population level 
and from experimental sleep restriction together with the original GWA study. We 
found suggestive association with a variant rs2031573 near KLF6 transcription 
factor, which associated with shorter sleep duration in the discovery sample and 
showed suggestive point wise association in the follow-up sample. While the 
association of this variant did not reach genome-wide significance, its relation to 
sleep was supported by functional evidence. Increased KLF6 expression associated 
with shorter sleep duration in a population-based sample. In addition, increased gene 
expression was also observed in an independent sample where sleep duration was 
experimentally restricted. Similarly, the expression levels of KLF6 associated with 
increased SWS duration. This association may be mediated through iNOS signalling 
since iNOS has a KLF6 binding site in its promoter region. These findings are 
consistent with that variants near KLF6 may contribute to sleep duration via iNOS 
mediated signaling. Since only two genome-wide association studies of sleep have 
been carried out so far and only one variant with genome-wide significance has been 
detected, more studies with larger sample size are needed in order to dissect the 
genetic factors in sleep regulation. Methodologically, our approach suggests that 
combining functional analysis with GWA studies, even with a relatively small 
sample size may be informative especially in the field of sleep research where 
precise phenotypes in population level can be hard to measure.  
This thesis evaluated the mechanism that connects short sleep and insufficient 
sleep amounts with cardiometabolic diseases. Short sleep duration is a risk factor for 
developing T2DM and obesity. We observed activation of immune reaction, down 
regulation of lipid transport and synthesis, and down-regulation of circadian 
pacemaker genes after experimentally induced sleep restriction. The data suggest 
that the activation of low-grade inflammation together with metabolic changes in 
cholesterol and lipid synthesis take place in sleep restriction. These changes may 
help to cope with short-term sleep debt but are likely to induce pathological changes 
in the long term. In contrast, we found that in population sample short sleep duration 
was related to increased blood cholesterol levels. It is likely that longer sleep 
deprivation has opposite effects on total cholesterol levels than short term sleep 
restriction. These findings may explain the well-established connection between 
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sleep and cardiometabolic diseases but the mechanisms controlling these changes 
remain still largely unexplored and need to be studied further. 
At the genetic level we studied the role of common genetic variation of sleep in 
somatic and psychiatric diseases. The variants in TRIB1 were associated with sleep 
and lipid traits. The association with sleep duration was independent from lipid 
levels, suggesting that TRIB1 polymorphisms may have an independent role in sleep 
regulation. These findings were supported by two observations: 1) TRIB1 RNA 
levels were increased after experimental sleep restriction and 2) the expression 
change in TRIB1 RNA expression levels associated with the changes in SWS 
duration.  
In the depression study we found that variants in adenosine metabolism associate 
with depression. The strongest finding was observed with ENT3 in females and it 
sustained multiple testing. The other most significant findings came with the 
adenosine transporters as well, rather than with the enzymes that catabolise 
adenosine. These data suggest that the adenosine transporters may have a larger role 
in the aetiology of depression than what has been thought before.  
In the association study with BD, we observed a genetic connection with 
chronotype and visual memory with CDH7 genotypes. Individuals with BD have a 
more variable circadian rhythm (Jones et al., 2005). Previously, variants in the 
circadian pacemaker genes have also been associated with BD (Benedetti et al., 
2007, Nievergelt et al., 2006, Soria et al., 2010). The phenotypes that were related to 
chronotype and seasonality were also associated with CDH7.  In addition, the CDH7 
variants that associated with cognitive tests were associated also with visual 
attention and visual memory, traits that all are related to visual processing of light. 
Previous studies of CDH7 have shown that it regulates the development of eye and 
retina (Faulkner-Jones et al., 1999, Luo et al., 2004). Together with previous 
findings our data suggest that the variants in CDH7 may be connected with BD 
trough their role in light-dark transitions. These findings suggest that sleep and 
psychiatric diseases are closely connected also on the genetic level.  
Interestingly, we were able to show that those individuals who carried the risk 
genotype of CDH7 for BD performed better in cognitive testing. These findings 
support the hypothesis that not all risk variants alone are malignant but require 
possibly other risk variants or specific environmental exposure. As noted earlier, 
risk factors for one trait can be beneficial for another trait. These themes should be 
considered more in detail in the field of psychiatric genetics. 
In these studies we used related phenotypes and endophenotypes to divide the 
study subjects. This was done in order to obtain phenotypically, and potentially also 
genetically more homogenous population. The data suggest that genetic variants in 
both psychiatric and somatic traits associate both with sleep traits and the disease 
phenotypes. The traits may either be comorbid or one may predispose for the other 
such as short sleep to metabolic diseases also on the genetic level or dyssynchrony 
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of circadian rhythm for BD. However, longitudinal studies as well as interventions 
will be important in revealing the causality of these associations. Our findings 
support using endophenotypes together with the disease phenotype in order to clean 
the phenotype. This approach will be useful especially with psychiatric diseases that 
contain a myriad of phenotypic interactions and present a mix of different 
phenotypic combinations. In addition, healthy individuals can be used to dissect 
normal variation with the phenotype. The findings presented in this thesis should, 
however, be interpreted in the light of following limitations. The discovery samples 
in the study were relatively small and had limited power to detect variants with 
genome-wide significance. Larger studies are thus needed in order to detect such 
variants. The phenotypes in the population cohorts were measured with 
questionnaires. In the case of sleep duration it is thus hard to distinguish between 
individuals who are natural short sleepers and who are sleep deprived. These 
limitations were partially overcome by combining the analyses with functional 
evidence and experimental sleep restriction. This study would have benefited from 
functional knock out animal models that could have been used to study the effects of 
the associating genes with sleep recordings.  
The relatively recent advantages in the development of technology in genetics 
have provided us with a growing number of tools to study complex genetic traits as 
well. This thesis has aimed to also use unconventional methods for integrating all 
possible material available. Surely also future advantages in exome sequencing 
studies will provide us with an even more thorough understanding of the enigmatic 
traits.  
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